

New and consolidated therapeutic options for pubertal induction in hypogonadism: in-depth review of the literature

Silvia Federici^{1,2*}, Giovanni Goggi^{1,2*}, Richard Quinton^{3,4}, Luca Giovanelli^{1,2}, Luca Persani^{1,2}, Biagio Cangiano^{1,2}, Marco Bonomi^{1,2}

¹ *Department of Medical Biotechnology and Translational Medicine, University of Milan, 20100 Milan, Italy*

² *Department of Endocrine and Metabolic Medicine, IRCCS Istituto Auxologico Italiano, 20100 Milan, Italy*

³ *Department of Endocrinology, Diabetes & Metabolism, Newcastle-upon-Tyne Hospitals, NE1 4LP, UK*

⁴ *Translational & Clinical Research Institute, University of Newcastle-upon-Tyne, NE1 4EP, UK*

* These Authors equally contributed to the manuscript as first Authors

Corresponding

Biagio Cangiano, MD
Dipartimento di Medicina Endocrino-Metabolica
IRCCS Istituto Auxologico Italiano
P.le Brescia 20 – 20149 Milano
Mail : b.cangiano@auxologico.it

Marco Bonomi, MD
Dipartimento di Medicina Endocrino-Metabolica
IRCCS Istituto Auxologico Italiano
P.le Brescia 20 – 20149 Milano
Phone: +39-02-619112390
Fax: +39-02-619223033
Mail: marco.bonomi@unimi.it ; m.bonomi@auxologico.it

Fundings

MB is partially supported by funds from IRCCS Istituto Auxologico Italiano: ICH-NGS 05C202_2012; KING 05C622_2016; PUBERTY032020 05X003

Disclosure summary

RQ has received speaker's honoraria and conference sponsorship from Bayer UK. The other Authors have no conflict of interest to disclose.


Accepted Manuscript

Abstract

Delayed puberty (DP) defines a retardation of onset/progression of sexual maturation beyond the expected age due to either a lack/delay of the hypothalamo-pituitary-gonadal (HPG) axis activation or a gonadal failure. DP usually gives rise to concern and uncertainty in patients and their families, potentially affecting their immediate psychosocial well-being and also creating longer-term psychosexual sequelae. The most frequent form of DP in younger teenagers is self-limiting and may not need any intervention. Conversely, DP due to hypogonadism requires prompt and specific treatment that we summarize in this review. Hormone therapy primarily targets genital maturation, development of secondary sexual characteristics and the achievement of target height in line with genetic potential, but other key standards of care include body composition and bone mass. Finally, pubertal induction should promote psychosexual development and mitigate both short- and long-term impairments comprising low self-esteem, social withdrawal, depression and psychosexual difficulties. Different therapeutic options for pubertal induction have been described for both males and females but we lack the necessary larger randomized trials to define the best approaches for both sexes. We provide an in-depth and updated literature review regarding therapeutic options for inducing puberty in males and females, particularly focusing on recent therapeutic refinements that better encompass the heterogeneity of this population, and underlining key differences in therapeutic timing and goals. We also highlight persistent shortcomings in clinical practice, wherein strategies directed at “the child with delayed puberty of uncertain aetiology” risk being misapplied to older adolescents likely to have permanent hypogonadism.

Keywords: idiopathic hypogonadotropic hypogonadism, GnRH deficiency, delayed puberty, testosterone, estradiol, gonadotropin

Graphical abstract



Accepted

INTRODUCTION

The conventional normal age-ranges for the beginning of puberty are reported to be between 8 and 13 years of age in females, and 9 to 14 in males although secular changes are reported. The first clinical signs marking its onset are the enlargement of testis volume (TV) ≥ 4 mL or scrotum enlargement/pigmentation in males (designating progression from Tanner's genital stage G1 to G2), and the appearance of breast buds in females (designating progression from Tanner stage B1 to B2) (1). Delayed puberty (DP) is defined as a retardation of pubertal onset beyond the expected age (more than 2-2.5 standard deviations values above the mean of the reference population) (2), thus no breast development by the age of 13 in girls and no testicular enlargement by the age of 14 in boys (1). The lack of Tanner stage progression after the beginning of puberty, evaluable on the base of available nomograms (3,4), together with a sudden drop in hormonal levels, has to be considered pathologic as well. The most common cause of DP in both sexes is constitutional delay of growth and puberty (CDGP) – a self-limited form of delayed puberty due to a transient GnRH deficiency, often considered an extreme of the normal spectrum of pubertal timing. Pathological causes of DP (listed in Table 1) must always be ruled out with an appropriate diagnostic work-up (5–7), particularly in the presence of clinical suspicion.

Differentiating between CDGP, functional and congenital hypogonadotropic hypogonadism (CHH) during early adolescence is particularly challenging due to the many overlapping clinical, biochemical and radiological features (5,6,8,9), but the distinction is a necessary one as these conditions then diverge hugely in respect of their long-term outcomes. Permanent forms of hypogonadism causing DP require specific treatment to induce or complete pubertal development, and reaching a correct and timely diagnosis thereof is crucial to promote patients' somatic and sexual maturation and psychosocial well-being. It is also vital not to

misdiagnose as CDGP those with retardation of growth and puberty due to parasellar lesion or systemic illness such as bowel disease or eating disorder.

We present herein an in-depth review of the literature regarding therapeutic options available for pubertal induction in both males and females with hypogonadism, beginning with the more consolidated approaches and then proceeding to more novel advances in the field, considering the heterogeneity of this population and underlining differences in therapeutic timing and goals. We emphasize that CDGP should be a diagnosis of exclusion and not of default: notably, among older adolescents approaching the end of their teenage years, CDGP is no longer the majority and should not be seriously considered beyond 18–20 years of age. Based on Bayesian principles, the adverse consequences of not intervening to pharmacologically induce puberty in a minority of minors with hypogonadism outweigh those of intervening – perhaps unnecessarily – in the majority with CDGP.

Goals and timing

Therapy should lead to the maturation of genitalia and of secondary sexual characteristics of patients with DP, whether young adolescents or older individuals who “slipped through the net”, and linear growth, body composition, muscle mass and normal bone density should also be achieved (2,10,11).

During the first phase of pubertal development, sex hormones play a crucial role in inducing the pubertal growth spurt and permit the achievement of body proportions and adult height in line with genetic potential. For instance, in CHH a delayed growth spurt on the background of otherwise preserved linear growth can lead to both taller stature (12) and segmental disproportion (13) compared to genetic potential, whereas failure to recognize and treat a systemic disease or parasellar lesions causing DP and growth retardation leads to a shorter adult height (14–16). Moreover, an excessive delay in puberty and/or in pubertal induction

may adversely affect bone health, although the data are not entirely consistent. According to several studies (17–20), adult men with history of DP present significantly decreased bone mineral density (BMD) levels at all sites, hence being at greater risk of osteoporotic fractures, and pubertal delay can lead to a lower peak bone mass in girls, as well (21). On the other hand, Bertelloni (22) and Yap (23) conclude that male patients with CDGP tend to have normal volumetric BMD, with conventional areal BMD appearing low due to altered skeletal phenotype. With particular regards to CHH, De Rosa and colleagues (24) found an inverse correlation between spinal BMD and the age at pubertal induction, thus supporting the importance of a timely diagnosis and intervention. Notably, histories of deficient treatment (inadequate dosage and/or long pauses) after diagnosis are also associated with impaired bone mass (25). Finally, pubertal induction must promote psychosexual development (26–28) and prevent psychosocial damage, including low self-esteem, body image concerns, social withdrawal and sexual inactivity in later life (29–31). In males with CHH, combined gonadotropin treatment can also promote the normal maturation (or indeed descent) of the testes (see below).

Thus, it is essential to promptly define the underlying pathogenesis in order to identify a tailored program of care. In contrast to CDGP, where a “*wait-and-see*” strategy would be an appropriate management since puberty should start spontaneously, pathological forms of DP need a specific therapeutic approach. A possible exception is represented by DP associated with functional central hypogonadism, in which the first line of action would be to remove or treat the underlying cause of HPG axis disorder, aiming to restore its correct functionality.

The optimal age to begin treatment in patients with known hypogonadism has not yet been universally established. Whenever genetics, clinical history or physical exam allow a timely diagnosis of either congenital or acquired forms of hypogonadism, a treatment within the physiological time frame of puberty is possible and therefore recommended (8). In particular,

clinical syndromes associated with hypergonadotropic hypogonadism can be diagnosed before birth or in early infancy, and gonadal insufficiency is confirmed by rising gonadotropins at the anticipated time of puberty. More rarely, patients with reproductive or non-reproductive clinical features typically associated with CHH (the so called “red flags”) might also receive a timely diagnosis (see Table 2) (6). Therefore, to recapitulate normal physiology and mitigate adverse outcomes, in such patients pubertal induction should be initiated no later than 14 years in males and 13 years in females. However, this “motherhood and apple pie” injunction to clinicians necessarily assumes an unrealistically precocious diagnosis of hypogonadism that is rarely achieved in practice, especially in those cases with a challenging differential diagnosis with CDGP. For the vast majority of hypogonadal patients the diagnosis cannot even begin to be considered until after a period of pubertal delay. This means that patients will receive necessarily their final diagnosis outside their physiological time frame, making it even more important to promptly complete the diagnostic workup and begin appropriate treatment. In practice, the diagnosis and treatment of CHH patients is typically delayed until very late adolescence even in developed countries, which is unacceptable. These delays reflect both the inertia of clinical referral pathways and the frequent misapplication by clinicians of management principles aligned with CDGP to adolescents with likely organic hypogonadism (32).

Whenever it is not possible to differentiate between CDGP and CHH, a short treatment with low doses of sex steroid hormones should be considered (i.e. testosterone gel 10 mg every second day or intramuscular testosterone enanthate 25-50 mg monthly): in fact, besides helping these patients psychologically, it can also help the clinician differentiate the self-limiting delayed puberties from persistent conditions, since CDGP patients will then generally initiate endogenous pubertal development (6,33).

Induction of puberty in males

Testosterone is the most frequently adopted pharmacological treatment in hypogonadal boys with DP, due to its efficacy at inducing secondary sexual characteristics, growth spurt, bone maturation and psychosexual development and its limited side effects and costs. However, testosterone alone cannot stimulate testicular growth or induce spermatogenesis, nor induce testicular descent in those with cryptorchidism (1,2,8,29), whereas these goals can all be achieved in most CHH patients with combined gonadotropin treatment (2,34–36), which may also give these patients a significant psychological encouragement and enhance their self-confidence (2). Early induction of spermatogenesis may reduce the time required to re-induce it in adult life (29,35,37). CHH patients treated with gonadotropins achieve an androgen profile (both testosterone precursors and metabolites) that is closer to normal biochemistry than what is achievable with testosterone treatment (38), although the clinical relevance of this finding remains uncertain.

There are no longer concerns as to whether prior testosterone replacement treatment (TRT) negatively impacts the subsequent spermatogenesis or TV response to gonadotropins in CHH patients: although earlier studies suggested that prior TRT was a negative prognostic factor (39), especially in patients with severe phenotype of CHH (TV < 3 ml) (40), a meta-analysis found no differences in the success rate of sperm appearance, nor in the mean sperm concentration between patients who previously received testosterone and those who did not (41). Moreover, a recent study by Rohayem et al. (34) showed that gonadotropin treatment in young CHH males successfully induces testicular growth and spermatogenesis, irrespective of previous testosterone treatment; however, although being not a statistically significant difference, it must be taken into account that both the rate of TRT naïve patients who reached a normal sperm concentration and also their mean sperm concentration itself were around double those of patients who previously completed pubertal induction with TRT (34).

Finally, another strategy to induce puberty in CHH involves pulsatile subcutaneous infusion of GnRH through a wearable minipump (42), but data on its comparative efficacy to gonadotropins are conflicting (43–45). Overall, considering its high cost, limited availability and the associated discomfort (44,46), the GnRH pump is a less feasible strategy in clinical practice to induce puberty in males, compared with exogenous gonadotropins.

Testosterone: types and routes of administration

There remains a dearth of studies directly comparing different testosterone protocols to induce pubertal development in males and thus no truly evidence-based guidelines regarding the optimal formulation and regimen for this purpose have ever been drawn up (47).

Intramuscular (IM) testosterone esters are the most frequently prescribed formulation for pubertal induction (48–51), in consideration of their relatively low cost (10,52) and wide experience of efficacy at inducing an adequate virilization (52). Nevertheless, intermediate-acting testosterone esters come with some disadvantages: younger adolescents may find it hard to tolerate such frequent and relatively painful injections (50), which could contribute to poor adherence. Moreover, they exhibit suboptimal pharmacokinetics with wide serum testosterone levels fluctuations between injections, from supraphysiological levels for the first few days, to subtherapeutic levels leading up to the next injection, sometimes associated with undesirable swings in energy, mood and libido (53–56), and greater risk of erythrocytosis (57).

Another consolidated formulation of testosterone is oral testosterone undecanoate (TU): being a tablet its administration is better tolerated than injections; moreover, since it is absorbed through the enteric lymphatic system, it bypasses hepatic first effect, therefore relatively lower doses can be administered compared to older oral formulations. However, its absorption is highly sensitive to the lipid content of meals, which makes it often unreliable;

besides its short half-life makes it necessary to administer multiple daily doses, with fluctuations in testosterone levels through the day (and possible compliance issues); finally, it is also not widely available (47,58). Most data concerning safety and efficacy of oral TU in young boys derive from studies performed on patients with CDGP rather than hypogonadism and, despite differences in doses and duration of therapy, they all found that treatment with oral TU was able to induce the maturation of secondary sexual characteristics (4,59,60), increase TV (59,60) and stimulate growth without an inappropriate advancement of bone age (4,59–62). However, the effects on predicted adult height were inconsistent, being either increased (4), reduced (62) or unchanged (60). Overall, these studies provide significant evidence that the administration of oral TU in boys with CDGP is both safe and effective at promoting pubertal development and growth without excessively advancing bone age. Similarly, long term treatment with oral TU was also proved to be both safe and effective at inducing pubertal development in boys with anorchia (63,64).

Finally, among the oldest testosterone formulations are testosterone pellets, implanted subcutaneously using a trocar into the lower abdominal wall. However, although relatively stable levels of testosterone are achievable, the overall pharmacokinetic profile is inferior to IM TU (see below). Moreover, they require a minor surgical procedure and are associated with risk of extrusion or infection (53). The literature data regarding the use of testosterone pellets for pubertal induction in young hypogonadal boys is very scarce: the only evidence available on this issue showed that 18 months of treatment with testosterone pellets in boys affected with different forms hypogonadism led to an appropriate growth, pubertal progression and psychosocial development, proving to be safe, effective and well tolerated by all patients (65)

Over the last few years, interest has grown in newer testosterone formulations that have begun to be used more widely in clinical practice. However, no formulations were designed

for inducing puberty in patients with hypogonadism, but rather as hormonal replacement therapy for adult hypogonadal males: therefore no standard of care exists for their use in pubertal induction and their pharmacokinetics and doses may not always be suitable for treating young prepubertal boys (see below). However, over the last decade a few studies have provided some evidence (see below).

Testosterone gels have the advantages of guaranteeing more stable serum testosterone levels over 24 hours and of providing good flexibility in dose adjustments (in particular, multidose dispenser can deliver as low doses as 10 mg per pump) (57,66). Unintentional skin-to-skin testosterone transfer is one of the most important adverse events of such formulation, since it is able to lead to inappropriate virilization of passively exposed women and children. Moreover, high costs might be a deterrent. To date, only few studies have investigated its efficacy in young boys with delayed puberty, but data seem promising regarding both efficacy and safety, although concerns remain as to degree of adherence by the average teenager: Rogol et al. reported a significant rise up to normal age-matched serum testosterone levels in young patients affected with primary hypogonadism treated with increasing doses of testosterone gel 1% for 6 months, despite no clinical meaningful changes were observed in terms of physical examination (more than half of patients were not naïve to testosterone, occurrence which may have limited such changes) (56); Chioma et al. reported that low daily doses of testosterone gel 2% administered for 3 months in boys with CDGP were able to significantly increase growth rate in such patients, with no significant differences compared to intramuscular testosterone (67); finally, Contreras et al. showed the effects of three different testosterone gel regimens (with different formulations and dosages) in three young hypogonadal patients with hepatic dysfunction, reporting the advancement of secondary sexual characteristics, an increase in height and in testosterone levels and a decrease in liver enzymes in each of them (68).

Another recent introduction in the field is long-acting intramuscular testosterone undecanoate (TU), although data are still scarce among patients with DP. The three studies (55,69,70) that investigated its efficacy at promoting pubertal development showed good results without significant adverse events, but they only recruited older adolescents (≥ 17 years old) or prepubertal hypogonadal adults. TU has a much lower frequency of injections compared to testosterone enanthate, which handily corresponds to the typical interval between clinic visits, potentially facilitating greater compliance; moreover, testosterone levels remain relatively stable between injections and, therefore, unpleasant swings in mood, energy or libido are generally not experienced by patients. On the other hand, its fixed dose and long half-life make it harder to progressively modulate serum testosterone levels in children undergoing pubertal induction: hence, there is a theoretical risk in younger boys of advancing bone age too rapidly and thereby inducing precocious maturation and fusion of epiphyses, impairing final adult height (71).

The FDA recently approved a new oral TU formulation characterized by a self-emulsifying drug delivery system: TU is dissolved within a mixture of lipids and a hydrophilic surfactant and this composition allows the solubilization of testosterone so that it can be absorbed through the intestinal lymphatic system irrespective of the lipid content of the previous meal (in contrast with the older oral TU which needs a fat-rich meal in order to be efficiently absorbed). To date, only a few phase-III clinical trials have evaluated the effects of this new formulation in the treatment of hypogonadism in adult males and data look promising in terms of both efficacy and safety (although the administration of new oral TU was shown to be associated with more mild gastrointestinal adverse effects and a 3-5 mmHg increase in systolic blood pressure) (72,73). Unfortunately, no data exist yet on their use for pubertal induction in prepubertal hypogonadal boys: hopefully, in the future trials will be performed on these patients as well.

Finally, FDA also recently approved the administration of subcutaneous testosterone enanthate via an auto-injector (SCTE-AI) as a new formulation of TRT for hypogonadal patients. Different studies show that a weekly administration of subcutaneous testosterone enanthate is safe, well tolerated and effective at allowing patients to achieve testosterone levels within the reference range (74–77). Besides its efficacy, SCTE-AI has also several advantages: first of all, testosterone can be easily self-administered through the auto-injector, a device which also reduces the sensation of needle-entry and pain; secondly, due to a reduced variability of testosterone levels, swings of mood, energy and libido are less likely to happen compared to intramuscular injections; finally, the ease of administration and its weekly regimen may lead to higher compliance compared to other formulations (74). To date, however, no data are available on the use of subcutaneous testosterone for pubertal induction in hypogonadal patients. Despite this, some evidence can be extrapolated from induction protocols used in transgender female-to-male (FtoM) patients. Several different testosterone esters and different regimens have been used so far for such purpose (78–81): for example, Olson et al (79) administered progressively increasing doses of subcutaneous testosterone cypionate for 6 months (first a biweekly dose of 25 mg for the first 8 weeks, then it was increased to 25 mg weekly for four weeks and, if tolerated, increased to 50 mg weekly, with most patients ending up on a final dose of 25 to 75 mg per week) to a small cohort of young (13-24 years old) FtoM patients and reported that such treatment was overall effective at achieving testosterone levels within the normal male range and at inducing amenorrhea, with little adverse impact on physiologic parameters (BMI, systolic blood pressure and alanine aminotransferase increased to statistically but non clinically significant levels) and few, mild side effects; similarly, Spratt et al (78) showed that progressively increasing doses of subcutaneous testosterone cypionate in FtoM patients (starting dose of 50 mg weekly, then doses were sequentially increased to achieve testosterone levels within the adult normal

range) were able to achieve testosterone levels within or above the normal male range, induce amenorrhoea, suppress oestradiol levels and induce male secondary sexual characteristics, proving to be an effective, safe and well accepted option for such purpose. Thus, subcutaneous testosterone esters, also with the possibility of administering lower doses at shorter time intervals might be a promising alternative for pubertal induction of hypogonadic cisgender boys.

The main characteristics of the formulations illustrated, with their advantages and disadvantages, are summarized in Table 3 (47,53,54,57,58,66,72–74).

Testosterone: proposed therapeutic schemes

In younger adolescents, a regimen of gradual testosterone titration is essential to recapitulate the progressive increase of serum testosterone during the physiology of normal puberty; in this way, both psychosexual and secondary sexual characteristics develop gradually, whilst optimization of growth and adult height is also ensured (29). Although concrete data are conspicuously lacking, there are reasonable concerns that too-rapid escalation of testosterone dose might lead to abrupt virilization (10) and accelerated psychosexual development, potentially increasing the risk of precocious sexual activity (8) and relational problems (10), and could also compromise adult height by inducing premature epiphyseal fusion (10,29,46). However, these concerns are largely theoretical and not relevant to older adolescents or adult males with CHH.

The best established regimen for pubertal induction involves the use of intermediate-acting intramuscular testosterone esters (in particular testosterone enanthate); ideally it should be started around the age of 12 years (1,46,82) with low doses of testosterone esters (e.g. 50 mg of testosterone enanthate) every 4 weeks (1,2,8,29), with the dose then be increased gradually (e.g. escalations of 50 mg every 6-12 months (1,2)), over a course of 24–36 months (2,8,29)

until reaching full adult dose (e.g. 200–250 mg every 2–4 weeks) (1,2). In hypogonadal patients come to medical attention only at late adolescence or in adulthood, testosterone dose-escalation should be faster as since adult height is no longer of concern (29), segmental disproportion may already be established and patients are by and large desperate to complete puberty as rapidly as possible (8): a higher initial dose (e.g. 100-200 mg of intramuscular testosterone enanthate monthly) (2,8) can be quickly increased to 250 mg monthly (2).

Regarding the use of intramuscular TU for pubertal induction, only few, small observational studies have recently been developed (55,69,70). To ensure a more gradual rise in testosterone levels, the investigators either omitted the usual loading dose at six weeks (69,70), or started with oral TU for a few months before switching to intramuscular TU (55). As already stated above, due to lack of data and the theoretical risks of advancing bone age too rapidly, intramuscular TU is not recommended to induce puberty in young boys with hypogonadism and is therefore reserved for older patients (≥ 17 years old) with hypogonadism who have achieved the majority of their linear growth potential (71), which in practice comprises around 50% of CHH patients, partly due to referral delays and medical procrastination (31).

Due to its favorable pharmacokinetics, lack of injections and flexibility for dose adjustment, testosterone gels administered through multidose dispenser offer significant advantages for pubertal induction in young adolescents, although the actual evidence remains scarce (56,67). An adequate starting dose for a 12–14 year-old would be 10 mg every second day (8), progressively increased to full adult dosing over the course of 24–36 months, depending on clinical response, but further studies are necessary to establish a standard of care.

Once again, despite the paucity of studies on the use of oral TU for pubertal induction in hypogonadal boys makes it difficult to design solid standards of care, it is reasonable to start

with low doses and then to progressively increase them as pubertal development proceeds: therefore it has been suggested to start with 40 mg every other day for 3 months, then 40 mg daily for 6-12 months and then progressively increase the dose up to 80-120 mg daily by 18-24 months from the beginning of treatment, when switching to parenteral formulation is usually made; the rate of increasing doses needs to be decided for each patient according to the progress of his linear growth, virilization and bone age advance (71).

The main studies which evaluated the effects of different testosterone formulations for pubertal induction are listed in Supplementary Table 1 (83) (<https://zenodo.org/record/5572710#.YWm24RpBxPZ>).

Gonadotropins: types and routes of administration

Pituitary gonadotropins are administered by subcutaneous self-injections and their use has gained ground in clinical practice in recent years, with several novel themes having emerged.

FSH is required to induce proliferation of immature Sertoli cells and spermatogonia, and to sustain TV and spermatogenesis (2,84,85). Three different preparations are available: human urinary FSH (uFSH), whether highly-purified or not, and recombinant human FSH (rhFSH) (41), with regular uFSH being far cheaper. A small retrospective study found that, compared to highly-purified uFSH, rhFSH achieved higher spermatozoa forward motility, a trend towards shorter time to achieve pregnancy and significantly faster appearance of spermatogenesis, despite achieving similar final sperm concentrations (86). However, a meta-analysis (41) reported no significant difference in the achievement of spermatogenesis or sperm concentrations among CHH adult patients treated with any form of FSH, suggesting no evident advantages of the newer preparations.

Due to its structural and functional homology with human LH and far longer half life, hCG is used to stimulate the production of endogenous testosterone from testicular Leydig cells, thereby inducing virilization, growth spurt, bone maturity and psychological development in the same manner as exogenous testosterone. Moreover, hCG also achieves physiologically high intratesticular testosterone concentrations that – via binding to androgen receptors on Sertoli cells – act in concert with FSH to induce germ and Sertoli cell proliferation and maturation and thereby achieve spermatogenesis (85). Both urinary and recombinant forms are now available, with a single subcutaneous injection of 2500 U of recombinant hCG – after a delay of about 12 hours – achieving a major increase in testosterone levels, peaking 72–96 hours later (mean peak level 34 nmol/L) and returning to baseline after 8 days (87). Finally, by inducing aromatase, hCG can also lead to gynecomastia due to increased conversion of androgens into oestrogens (88). Although hCG can be used alone, in CHH it should generally be used in support of FSH therapy (see below). Despite its possible advantages on testicular growth and potentially in future fertility, gonadotropin treatment is considered off-label for pubertal induction.

Gonadotropins: proposed therapeutic schemes and applications

Among studies that have investigated their use for pubertal induction, few were randomized controlled trials and, overall, were heterogeneous in terms of patient numbers, ages (ranging from adolescence to adulthood), length of observation and therapeutic protocol adopted, whether with hCG alone or in combination with FSH. The main studies are listed in Supplementary Table 2 (83) (<https://zenodo.org/record/5572710#.YWm24RpBxPZ>).

HCG monotherapy induces testicular growth (35,89–91) and spermatogenesis (35,89,90,92), especially in patients with a post-pubertal onset of CHH (basal TV > 4 ml) (89,90), but combination therapy with FSH achieves notably better results in males starting off with

prepubertal TV, with significantly more patients showing evidence of spermatogenesis and at greater sperm densities (35,91,93–96) and higher final TV (34,35,93,95,96). However, larger randomized controlled trials comparing the effects of hCG-alone vs hCG+FSH are required to better define these advantages.

Animal studies (97,98) have suggested a limited time window in prepubertal subjects, wherein FSH can optimally induce Sertoli and germ cell proliferation in immature testes, but which then begins to close with the onset of testosterone secretion by Leydig cells (41,85). Therefore, several investigators trialed pretreatment with rhFSH before starting either GnRH therapy (85) or combined therapy with rhFSH/hCG (84,99), with the rationale of inducing Sertoli cell proliferation before these cell numbers stabilized with the onset of androgen-induced cell maturation. Among CHH patients pretreated with rhFSH before starting combination therapy, almost all those who were able to provide semen samples had sperm cells in their ejaculate, which was an encouraging result considering their small initial TV (< 3 ml) (84). Subsequently, Dwyer et al. (85) reported that pretreatment with rhFSH before GnRH therapy led to a greater increase in TV, larger final TV, shorter time-to-spermatogenesis, greater numbers (100%) achieving spermatogenesis and higher maximal sperm count, albeit all falling short of statistical significance. Nonetheless, they demonstrated an increase in the number of Sertoli cells and spermatogonia together with histological maturation of the testes and a doubling in TV during the initial phase of rhFSH monotherapy (85). Overall, these results suggest a possible beneficial effect of a rhFSH pretreatment, which indeed mimics the physiological pattern of gonadotropin activation in early puberty. CHH patients with history of cryptorchidism were excluded from these studies, but it is precisely these individuals with depleted Sertoli and germ cell mass who potentially stand to derive greatest advantage from an initial phase of FSH monotherapy. In all these studies, patients undergoing pretreatment with rhFSH necessarily delayed the beginning of hCG-

induced virilization, which is physically and psychologically undesirable. However, another option would have been to deploy exogenous testosterone, of which relatively little would diffuse into the interstitial fluid surrounding Sertoli cells. Overall, a simpler strategy might be to start combined FSH and hCG treatment contemporaneously, while whether or not an initial treatment with hCG alone would be less effective than pretreating patients with FSH is not known.

Once spermatogenesis is induced with either GnRH or hCG/FSH treatment, it can be maintained with hCG-alone for a variable amount of time (100,101), *i.e.* once mature seminiferous tubules have arisen with combined gonadotropin treatment, Sertoli cells can continue to sustain spermatogenesis even with intermittent exposure to FSH. Following this rationale, Zhang et al (91) recently compared the effects of continuous versus intermittent administration of uFSH in prepubertal CHH patients treated with combined therapy hCG/uFSH, reporting no significant differences between the two regimens in terms of either final TV, testosterone levels, virilization, timing of spermatogenesis or sperm concentrations. Therefore, combination therapy with continual hCG and intermittent uFSH might represent a non-inferior alternative regimen to induce virilization and spermatogenesis in prepubertal CHH patients at considerable lower cost (91).

Finally, recent studies – including one randomized clinical trial – have reported that cryptorchidism (especially if bilateral), low initial TV, and a strong genetic background (all indicators of more severe GnRH deficiency since intrauterine life) represent the major negative predictors of response to gonadotropin treatment in terms of final TV and sperm concentration achieved (13,34). Nevertheless, even among patients with these negative predictors, gonadotropin therapy can still be successful in achieving biological fatherhood (35,84,102).

In summary, despite the heterogeneity of the available data, some pillars of gonadotropin therapy can be distinguished. hCG promotes virilization, growth spurt, sexual and psychosexual development, while the early addition of FSH grants a higher efficacy in terms of both TV increase and achievement of spermatogenesis and a much higher efficacy in achieving testicular descent (29). In this context, pretreatment with FSH for a few months may be the key to better maturation of testicular micro-architecture (85). Although no standard of care currently exists, some studies used fixed doses of FSH throughout (91,96) and others allowed for increasing doses when initial TV increase or spermatogenesis were disappointing (36,40). In pubertal induction, the hCG dose should start off low and then progressively increase during the course of treatment (34,35,40), according to a regular testing of serum testosterone and estradiol and clinical assessment. However, patients already treated with testosterone might start treatment with higher initial doses compared to entirely prepubertal patients (34,40).

Besides being able to induce pubertal development in hypogonadal boys with DP, gonadotropins can also be used to replace the so-called “mini-puberty” in male newborns with early signs of CHH: the term “mini-puberty” refers to the transient activation of the HPG axis that begins around 32 weeks of gestation and is sustained for the first 4–6 months of life in boys and the first 1–2 years in girls (29). This phenomenon contributes to the final stages of testicular descent into the scrotum and an increase in penile length; accordingly, the earliest neonatal signs of CHH are cryptorchidism and micropenis (103). The potential impact of mini-puberty on adult sexuality and fertility represents the strongest argument supporting gonadotropin replacement therapy in newborn boys with severe CHH (104). In this setting, early data are encouraging, albeit featuring small and heterogeneous samples of patients and different treatment regimens (105–110). In fact, neonatal mini-puberty replacement can have beneficial effects on testicular endocrine function and genital

development, thus preventing psychological discomfort during adolescence. It also helps testes to descend to the scrotal position and/or to fix them there. Further prospective controlled trials are required to address the potential long-lasting advantages on adult reproduction health, by assessing additional outcomes, such as sperm count after pubertal induction. Overall, we find it reasonable to offer this therapeutic option to newborn boys with severe CHH (micropenis and/or cryptorchidism), while explaining to their parents present uncertainties concerning long-term effectiveness and safety, as well as arranging to closely follow them up at the age of normal pubertal onset.

Patients' follow-up and life-long replacement therapy

During pubertal induction, careful clinical monitoring is required to evaluate genital maturation and virilization, growth rate and potential side effects. Periodic reassessment of bone age may assist the physician in determining the adequacy of hormonal replacement therapy in younger adolescents, but hold little clinical relevance in older patients who have already reached or are close to reaching final adult height. Patients' adherence and satisfaction with treatment results should also be taken into consideration (8).

The adverse events of hormone therapy are dose-dependent, with the most concerning ones related to testosterone and hCG being erythrocytosis and premature epiphyseal closure, but also including aggressivity, mood swings, gynecomastia and priapism when doses are greatly excessive. Older males may experience androgenic alopecia even at optimal doses. Local side effects of IM administration are pain and erythema at injections site (1,2). Despite the lack of strong evidence, we suggest monitoring hematocrit and serum testosterone levels, in order to avoid overtreatment and ensure a gradual rise of serum testosterone, ideally within the reference range for pubertal stage (111) for each laboratory. Moreover, since inhibin B and AMH are released from Sertoli cells in response to FSH, their levels both at baseline and

after exogenous FSH administration might represent a useful marker to predict the spermatogenic response of the testicles to gonadotropin therapy (34). Measurement of bone mineral density should also be considered at baseline in patients with risk factors for low BMD (112) and repeated once pubertal induction has been completed: in case it turns out to be low, it should be reassessed within 3-5 years.

TV should be periodically assessed and ultrasonography provides the most accurate measurement, while Prader orchidometer tends to overestimate TV, although it correlates well with ultrasonography and therefore can be a reliable surrogate in clinical practice (113). An increase of TV during testosterone therapy suggests that activation of the HPG axis has occurred. Since androgens have been suggested to have a positive priming effect on GnRH production and release (6,33), testosterone treatment could lead to an activation of HPG axis in about 10-20% of patients affected with CHH, an event known as “reversal” (8). When reversal is clinically suspected (*e.g.* through rising TV or gonadotropin levels, or an unexpected pregnancy), testosterone therapy should be withdrawn and levels of LH, FSH and testosterone reassessed (2,8). Moreover, a periodic reassessment of hormonal values off therapy should be considered, even if how often and up to what age remain open to question. However, since endogenous GnRH reactivation does not always persist indefinitely, these patients experiencing reversal need to be monitored clinically through a regular follow-up program in any case (8,114).

With the exception of CHH men experiencing reversal, patients with DP due to hypogonadism continue to be treated with testosterone lifelong as per any hypogonadal man (115). Before switching to TRT, CHH patients previously treated with gonadotropins can perform a semen analysis to evaluate the response of spermatogenesis after treatment and to detect subjects at risk for inadequate sperm-recovery later in adult life, giving them the possibility of sperm cryopreservation (despite the high costs) and a chance for future fertility

(34). Otherwise, gonadotropin therapy can be simply reintroduced in later life when fertility is desired, (2,8).

Induction of puberty in females

In females, adequate maturation of secondary sex characteristics is achieved with estrogen alone, while the main role of progesterone is to prevent endometrial hyperplasia. Indeed, clinical experience suggests that premature treatment with a progestogen may be deleterious to both final breast and probably also final uterine maturation.

In girls with hypothalamic-pituitary disease, another treatment option is in principle represented by gonadotropins or pulsatile GnRH pump (in those with an intact pituitary gland). While there are some anecdotal experiences with the use of the pulsatile GnRH pump for pubertal induction in females (116), there are no protocols for pubertal induction with gonadotropins. Stimulation with gonadotropins would be very complex, since it would have to mimic the hormonal pattern characterised by an increasing amplitude of FSH and LH pulses, that in turn induce ovarian steroidogenesis, until it replicates the cyclical pattern that allows ovulation to occur in the late stages of puberty; such strategy would also require close monitoring because of the risk of ovarian hyperstimulation. Unlike in males (see above), the complexity and cost of this approach are not counterbalanced by any significant known advantage over the use of oestrogen alone, therefore GnRH and gonadotropins are deployed only in adulthood to induce ovulation when pregnancy is desired. Pulsatile GnRH treatment is an effective and appropriate method to achieve normal ovarian function, with the advantage of inducing mono-follicular development, physiologic oestrogen levels, and normal luteal phase function; however, it is not effective in women with pituitary damage and most patients find it difficult to carry a pump continuously. Daily injections of gonadotropins are a better tolerated and more suitable treatment option for the induction of ovulation. In

women with hypogonadotropic hypogonadism, differently from conventional treatment (FSH followed by hCG or LH to trigger ovulation), the additional administration of LH is required to stimulate local production of androgen substrates by theca cells, which facilitates sufficient secretion of estradiol by the dominant follicle. Protocols involve treatment with highly purified human menopausal gonadotropins (hMG) or recombinant human gonadotropins (rhFSH and rhLH). This therapeutic option can be associated with increased risk of multiple follicular growth and ovarian hyperstimulation syndrome, due to the supra-physiologic follicular stimulus (117,118).

In recent years, the discovery of novel hypothalamic neuropeptides and the description of their physiological mechanisms have enabled the development of pharmaceutical agonists and antagonists. In particular, the use of kisspeptin agonists has been evaluated in the treatment of pubertal delay associated with decreased LH secretion, such as hypothalamic amenorrhoea and CHH resulting from mutations leading to loss of signalling of these neuropeptides (Kisspeptin and neurokinin B). Although further research is needed before kisspeptin analogs become incorporated into clinical practice, these findings suggest a number of novel approaches to treating dysfunctions of the reproductive system (119,120).

Estrogens are responsible for bone mass accrual and skeletal maturation, with a diphasic effect on long bone growth (inducing growth at low concentrations and epiphyseal closure at high concentrations), change in body composition, neurocognitive maturation and, of course, sexual development (121). Adequate uterine growth is also essential, since poor development – which is unfortunately all too common in hypogonadal women who underwent pubertal induction – can impact adversely on fertility and pregnancy outcomes.

Estrogens: types and routes of administration

Several types of compounds and routes of administration are available, with clinical differences in benefits and risks that have been extensively studied in post-menopausal and adult women, therefore applying these studies to adolescents represents an extrapolation. Since adolescents with hypogonadism will need estrogen therapy for around 4 decades, the choice of medication is critical. However, as there are no licensed hormone preparations for pubertal induction, the off-label use of hormone formulations licensed for adult women (and in practice formulated for the suppression of vasomotor symptoms post-menopause) is unavoidable.

Historically, some clinicians prescribed ethinylestradiol (EE – a synthetic estrogen) or conjugate equine oestrogens (CEE - a xenoestrogen) to induce puberty in girls, but there has recently been a sensible reversion to physiological human 17β -estradiol (17β -E₂), whether transdermal or oral (32). Indeed, emerging data demonstrate greater safety and efficacy associated with 17β -E₂ use compared with EE or CEE (122–126) and many Authors consequently discourage the use of anything but native 17β -E₂ (71,127–129). The transdermal route bypasses the hepatic first-pass effect, whereas oral oestrogens are metabolized by the liver before reaching the systemic circulation. Therefore, to achieve adequate systemic concentrations with oral oestradiol, the liver is exposed to supraphysiologic levels, resulting in an increase in pro-coagulation factors, SHBG and other binding proteins, triglycerides and inflammation markers (130). This may explain why oral, but not transdermal oestrogen delivery, is associated with a greater thromboembolic risk (131–138) and can have deleterious effects on body composition and lipid oxidation (139), glucose metabolism (140), and potentially induce peripheral resistance to GH in the liver by suppressing IGF-1 secretion/production (141,142). However, an alternative explanation is that most of these studies compared transdermal 17β -E₂ with oral CEE or EE, so the key

benefit may in fact reside in the choice of compound ($17\beta\text{-E}_2$) rather than with the transdermal route, something that had previously emerged in the transgender literature for induction and maintenance of feminization (143).

In young girls with hypogonadism the clinical outcomes of pubertal induction with different formulations of oestrogen were collected from isolated experiences, small underpowered observational studies and small clinical trials. Most of these studies were conducted on girls with Turner syndrome (TS), a population with clinical peculiarities in terms of treatment goals and risk factors. Therefore, it cannot be assumed that the evidence on the outcomes of oestrogen treatment is necessarily comparable for all DP-associated conditions.

Most studies (144–147) failed to demonstrate that different routes of administration result in different biochemical profiles (markers of inflammation, lipid metabolism, IGF1 and growth, insulin resistance, liver enzymes and renin) as markers of metabolic outcomes, probably due to the abovementioned limitations. On the other hand, treatment with E_2 (144), especially in the transdermal form (145), resulted in higher estradiol levels and more effective feminization at the selected doses administered. These findings also suggest that dose equivalences based on clinical practice or extrapolation from published equivalences in adults (127,148) may be incorrect. Therefore, measuring oestrogen levels should now be considered core to both dosimetry and ascertainment of patient adherence. This is routinely feasible during treatment with $17\beta\text{-E}_2$, albeit with certain limitations (see below), but cannot be done reliably for CEE and not at all for EE. Besides, even if the route of delivery of $17\beta\text{-E}_2$ does not differentially affect body composition and metabolic parameters when E_2 concentrations are titrated to the normal range, total oestrogen exposure (E_1 , E_1S level and total bioestrogen) is significantly higher with oral $17\beta\text{-E}_2$, meaning that transdermal $17\beta\text{-E}_2$ (TDE) achieves a more physiological oestrogen milieu (147,149). Moreover, Torres-Santiago et al. (147) show a tendency to lower IGF-1 and significantly higher levels of SHBG in the oral group, as

evidence of a stronger hepatic effect of oral oestrogens. A follow-on study confirmed this finding and illustrated that common feminizing doses of oral 17β -E₂ result in substantial accumulation of unphysiological genotoxic metabolites compared to transdermal estradiol, although further studies are needed to determine whether any of this is clinically relevant (150). Finally, a more favourable impact of transdermal oestrogens on some surrogate markers of cardiovascular risk (including fasting glucose, total cholesterol and triglyceride concentrations) and BMD compared to oral oestrogens was found in a systematic review and meta-analysis (151).

The main formulations available are reported in Table 4 with some mention of their pharmacologic characteristics (130). Transdermal estradiol is usually delivered in patch form in pubertal induction, which makes it easier to administer specific doses of 17β -E₂ by cutting up a matrix patch (reservoir patches cannot be cut), in order to facilitate dose adjustment in the absence of low dose products specifically designed for this purpose. Transdermal 17β -E₂ gel is not currently used for pubertal induction, both because of the difficulty of administering low doses with currently available formulations, and also because only one fairly dated paper proposing a gel induction scheme has been published (152). No data on dose equivalence between estradiol patches and gel is available in younger patients, although some Authors have now begun to propose gel as an alternative in pubertal induction (153). As for other formulations of estradiol (injected estradiol valerate), there is very limited clinical experience (and even more limited published data), whereas vaginal rings are inappropriate for prepubertal/early pubertal girls.

In conclusion, transdermal 17β -E₂ should be considered as the preferred choice, as suggested by most Authors (154). However, patients' preferences for oral oestrogen should also be taken into account. The use of EE and CEE should nevertheless be avoided.

Progesterone: types and routes of administration

In addition to oestrogen replacement therapy, progestogen is required to induce menstrual cycles, to prevent endometrial hyperplasia and to minimize irregular bleeding. However, no data are currently available on neither its use in young girls with hypogonadism nor its metabolic effects, whereas several studies evaluated the effects of progestin therapy in adults (130,155–161). Each progestin exerts a certain impact depending on their affinity for progesterone, glucocorticoid, mineralocorticoid, and androgen receptors, resulting in different properties that can translate to very different clinical effects (162).

Options for treatment mainly include micronized progesterone (MP) (which is bioidentical to endogenous progesterone), oral medroxyprogesterone acetate (MPA), norethisterone acetate (NEA) and dydrogesterone. MPA is the conventional progestin widely used in the past years, however MP has demonstrated increased safety in several studies and clinical trials compared to MPA, concerning breast cancer risk, metabolic impact and thromboembolic events, and gives good cycle control without significant side effects (157,158). NEA is the most androgenic, and therefore, possibly the least suited progestogen for younger girls, while dydrogesterone is available in many countries only as a part of combined HRT preparations. Therefore, MP has been recommended in most of the recent expert consensus documents (8,128,154). The principal characteristics of commonly used progestogens are discussed in Table 5.

Progestogens are usually given for 12–14 consecutive days every month at the lowest dose that achieves complete shedding of the endometrium, but the frequency of withdrawal bleeding may be adjusted according to the patient's wishes, as long as progestogen is administered at least every 2–3 months to avoid endometrial hypertrophy. Continuous administration of progestins for those who do not desire to have menstrual bleeding can be also considered. In practice, many postmenopausal women choose to insert capsules of

micronized progesterone vaginally rather than taking them orally, to mitigate gastrointestinal side-effects, but the product licence does not reflect this.

Proposed therapeutic schemes

Review of the literature highlights several relevant studies over the last two decades (144,145,152,163–166) presenting schemes of ERT for pubertal induction, difficult to compare due to different types and routes of administration, populations studied and age at ERT start.

Overall, a progressive increase in the dose is suggested, both to recapitulate normal puberty as far as possible and because excessive doses might lead to premature epiphyseal fusion and a reduction of adult height, impaired bone mineralization, and poor uterine and breast maturation (prominent and underdeveloped breasts).

Several years ago, some Authors (127,163,167) proposed to start induction with a low dose of transdermal 17β -E₂, corresponding to about 0.1 μ g TDE/kg, to be applied only at night, and then to be carefully increased before midpubertal levels are reached, in order to mimic the spontaneous estrogenic levels in the early pubertal range (peak value between 10 and 40 pmol/L) as well as the diurnal pattern of serum 17β -E₂. The rationale of this cautious approach is that maintaining these low levels of 17β -E₂ probably not only does it promote breast maturation, but it also increases growth velocity (as it is well known that peak height velocity in girls is observed in early puberty). The induction regimen consisting in low growth-promoting TDE doses for 18–24 months (starting from 0.1 μ g/kg to doubling every 6 months) based on body weight with initial overnight ERT, and adjusting the patch size to achieve target serum estradiol levels, as proposed by Davenport (127), is still one of the most widely used regimens to date and has been advocated by several Authors in recent publications (2,8,154). However, no clinical study has yet demonstrated any actual

superiority of the initial overnight treatment. In addition, early studies in TS were primarily focused on maximising adult height, with the opportunity to initiate age-appropriate oestrogen replacement all too frequently overlooked. Therefore, although a very slow approach may allow patients to achieve a greater stature through a more delayed epiphyseal fusion, it cannot be assumed that the clinical concerns and outcomes of oestrogen treatment are identical for all conditions associated with DP. One recent study (164) investigated faster protocols of induction in TS (first two months 12.5 µg/24 h, thereafter 25.0 µg/24 h until breakthrough bleeding), devised especially for girls with delayed diagnosis and/or initiation of oestrogen treatment, considering that in such conditions a 2- to 3-year model for induction of puberty may not be optimal: the Authors found a satisfactory rate of progression through pubertal stages, no influence on growth potential, and a satisfactory increase in uterine volume, that did not correlate with the duration of treatment or the dose of estradiol per kilogram of the initial body weight. Other two different protocols were adopted in clinical studies comparing TDE with oral ERT (144,145), with an initial dose of TDE of 12.5 µg and 25 µg respectively, showing that treatment with TDE resulted in higher estradiol levels, more effective feminization (144), faster bone accrual at the spine and increased uterine growth compared with CEE regimens (145). Lastly, a more simplified regimen (168) proposed to start with one quarter of a 25 µg patch, slowly increasing the dosage up to adult dose over 2–2.5 years (when progestogen is added), while other Authors suggest starting with one quarter of a 25 µg patch applied mid-week (128), to reduce the initial doses while avoiding to cut the patch into small fractions.

Concerning oral 17β -E₂, a well-established regimen proposed by Delemarre (52) suggests starting from 5 µg/kg of oral 17β -estradiol per day, doubling every 6 months until an adult dose of 2 mg per day in 2 years. However, a therapeutic regimen based on body weight is laborious and complex to deliver, especially for oral delivery. In this regard, a study by

Labarta et al (166) shows that a simplified incremental fixed dose can provide satisfactory pubertal development not inferior to individualised dose depending on weight and therefore it might be preferable as it is simpler. Indeed, a regimen proposed most recently by Zacharin et al (168) aims to an easier administration, starting at 0.5 mg every second day for about 3 months, increasing to 0.5 mg daily for 6–9 months, then 1 mg/day for about 12 months and finally increasing to an adult dose of 2 mg/day.

The main studies which evaluated the effects of different estrogen formulations and regimens for pubertal induction are listed in the Supplementary Table 3 (83) (<https://zenodo.org/record/5572710#.YWm24RpBxPZ>).

On the whole, despite the different regimens used, the dynamics of breast maturation is quite uniform in the cited studies, with the achievement of stage B2 during the first six months and B4 after approximately 2 years, which is comparable to spontaneous puberty (154,164). Data on uterine maturation are less reassuring: a recent study (169) assessing uterine parameters in hypogonadal women who had undergone pubertal induction found that uterine growth is often compromised regardless of diagnosis, despite standard oestrogen therapy. This observation could be due to inadequate oestrogen replacement doses, as suggested by an association between serum estradiol levels and uterine dimensions. However, neither the type of ERT nor its dose were linked to uterine size parameters. Moreover, no significant correlation between the age of initiation of therapy or menarcheal age and uterine size was found. It has also been reported that treatment with non-physiological oestro-progestin regimes gives worse results in terms of uterine development (170).

Considering the wide inhomogeneities of type and dose of therapy, age of initiation and population treated, carefully designed studies are required to confirm these data and to indicate the most effective induction scheme to ensure optimal uterine development. It has been hypothesised that there might be a “critical window” for uterine development during

adolescence, outside of which reduced size cannot subsequently be recovered. Although this is not clearly substantiated, the existence of a precise timing in uterine maturation might be suggested by the evidence that only during pubertal development there is a significant correlation between uterine volume and oestradiol concentration and the changes in uterine size are more striking at Tanner stage B3 and B4 (171–173).

In summary, treatment should be initiated with a starting dose of approximately 10% of the adult replacement dose and increased (by increments of 1.5 to 2-fold) every 6 months over a 2 to 3-year period (or less in older adolescents or young women). After at least 2 years of unopposed oestrogen, or if more than one episode of significant breakthrough bleeding occurs, it is necessary to consider a progestin to induce withdrawal bleeding, but only if adult breast and uterine conformation has been achieved. We recommend that, if symptoms of endometrial hyperplasia develop when breasts or uterus are not yet fully developed, then a slight reduction in 17β -E₂ dose should be considered instead of introducing the progestin, although we acknowledge the lack of direct evidence. However, in recognition that physiologically progesterone levels only rise substantially in the late stages of puberty (174), when ovulatory cycling becomes effective, and that it plays a role in both the breast and the uterus (175), it seems to us that following this approach that aims to recapitulate normal physiology represents the path of lowest risk.

It should be highlighted that the approach must be individualized, depending on the specific characteristic, circumstances, and desires of patients. When hypogonadism is diagnosed late, which is very common especially in patients with CHH, or it develops after spontaneous pubertal start, oestrogen dosing regimens can progress more rapidly, especially for those in whom adult height is not a concern.

Patients' follow-up and life-long replacement therapy

For both transdermal and oral 17β -E₂ induction regimens, we suggest checking estradiol levels after starting treatment and after dose changes, ideally with an ultrasensitive assay (although unfortunately it is not widely available). To date, there are no general recommendations regarding the timing of blood sampling in relation to 17β -E₂ administration and measurements of its levels can be influenced by absorption, metabolism, and user-related discrepancies. Despite these limitations, monitoring blood concentrations of oestradiol is a useful complementary tool to clinical objectivity for assessing compliance and guiding treatment choices in titration. Even if the treating physician has no access to a laboratory with a sensitive method for E₂ measurements, some Authors suggest that a value above 40 pmol/L should be considered as a marker of an excessive starting dose in a 12–14 year-old (163). Ideally, serum estradiol levels should progressively increase with each dose change and remain <180 pmol/L until full dose is reached (e.g. 50 µg of TDE), in order to accelerate linear growth without rapidly advancing bone maturation (127). For girls completing puberty, an adult target 17β -E₂ concentration around 350 pmol/L should be aimed for during therapy (149), similar to what is sensibly recommended in transgender women (143).

Pelvic ultrasound should be performed during pubertal induction and upon completion, to document the uterine size and shape and to evaluate the endometrial thickness and hence the optimal timing for progestin introduction. For uterine length, a cut-off of 65 mm is commonly used for maturity, based on the normative data by Griffin et al (176). It would be important the appreciation of uterine size in its entirety rather than relying on a single measurement, as this may provide false reassurance in terms of adequate development; however, there is variation in the literature as to the criteria comprising uterine maturity. In fact, during pubertal development the uterus also changes from tubular to 'pear' shaped and the ratio of the corpus to the cervix changes from being approximately 1:1 before puberty, to between 2:1

and 3:1 after puberty. A normative age-matched model of uterine volume was reported by Kelsey et al, with a predicted post-pubertal uterine volume of 25.8 cm³ (68% prediction limit 25.8-77.8 cm³) (173), while Burt et al provided references based on a eugonadal control population for three-plane diameters (total uterine length, anterior-posterior, transverse), volume and fundal-cervical ratio (169).

Screening for thromboembolic risk should be performed only in girls with a personal or family history, considering that an increased risk does not preclude oestrogen therapy, but requires a careful monitoring of haematological parameters (154). However, even if no other routine screening or monitoring tests are required they may be prompted by specific symptoms or concerns (177). As for BMD monitoring, the same approach discussed about male patients can be followed (see above).

ERT must be maintained until at least the average age of physiological menopause (51-52 years of age), but in practice many hypogonadal women will have received inadequate treatment in earlier life or had prolonged breaks in therapy, and so should be encouraged to continue a while longer. Progestogens, that can be added either cyclically or continuously, are available either as single agents or in combined formulation with oestrogen. European consensus guidelines for CHH do not recommend the combined oral contraceptive pill (COCP) (8) even though these continue to be prescribed through force of habit. Emerging data show that COCP is less favourable in BMD improvement, uterine parameters and long-term cardio-metabolic health compared with a physiological oestrogen replacement, particularly in older females. Nevertheless, it is clearly better to prescribe COCP than nothing at all, although packs should generally be taken back-to-back to avoid the risk of re-exposure to hypogonadism for 1-week-in-4 (124,129,178,179).

Conclusions

Pubertal induction needs to be performed within a physiological timeframe, in order to guarantee harmonious growth, sexual and psychological development. Hitherto, mainly studies with small case series or isolated experiences have been conducted for pubertal induction, often recruiting patients with different etiologies of hypogonadism or within broad age ranges at the start of treatment. It is now hopeful to have carefully designed studies performed among specific and uniform populations, in order to establish which treatment protocol is the most effective in each clinical condition, considering the heterogeneity of the populations to treat (180). Furthermore, as some treatments are still off-label, despite being already validated in clinical practice (such as gonadotropin treatment), multicentre RCTs would allow to officially extend the indication of these drugs to pubertal induction in young patients. These will need to be funded by national agencies, given that sex hormones are by and large low-cost drugs for which the costs of applying for a variation in product licence are excessive compared with the additional earnings that would accrue to the relevant pharmaceutical company.

Hitherto, no standard of care exists for pubertal induction, however some treatment strategies have consolidated in clinical practice. Useful tips for clinical practice in terms of both treatment strategies and clinical, laboratory and instrumental assessments during follow-up are listed in Table 6.

References

1. **Dunkel L, Quinton R.** Transition in endocrinology: Induction of puberty. *Eur. J. Endocrinol.* 2014;170(6). doi:10.1530/EJE-13-0894.
2. **Young J, Xu C, Papadakis GE, Acierno JS, Maione L, Hietamäki J, Raivio T, Pitteloud N.** Clinical Management of Congenital Hypogonadotropic Hypogonadism. *Endocr. Rev.* 2019;40(2):669–710.
3. **Johansen ML, Hagen CP, Mieritz MG, Wolthers OD, Heuck C, Petersen JH, Juul A.** Pubertal progression and reproductive hormones in healthy girls with transient thelarche. *J. Clin. Endocrinol. Metab.* 2017;102(3):1001–1008.
4. **Lawaetz JG, Hagen CP, Mieritz MG, Jensen MB, Petersen JH, Juul A.** Evaluation of 451 Danish boys with delayed puberty: Diagnostic use of a new puberty nomogram and effects of oral testosterone therapy. *J. Clin. Endocrinol. Metab.* 2015;100(4):1376–1385.
5. **Bollino A, Cangiano B, Goggi G, Federici S, Duminuco P, Giovanelli L, Galazzi E, Vezzoli V, Persani L, Bonomi M.** Pubertal delay: the challenge of a timely differential diagnosis between congenital hypogonadotropic hypogonadism and constitutional delay of growth and puberty. *Minerva Pediatr.* 2020;72(4):278–287.
6. **Persani L, Bonomi M, Cools M, Dattani M, Dunkel L, Gravholt CH, Juul A.** ENDO-ERN expert opinion on the differential diagnosis of pubertal delay. *Endocrine* 2021;71(3):681–688.
7. **Abitbol L, Zborovski S, Palmert MR.** Evaluation of delayed puberty: What diagnostic tests should be performed in the seemingly otherwise well adolescent? *Arch. Dis. Child.* 2016;101(8):767–771.

8. **Boehm U, Bouloux PM, Dattani MT, De Roux N, Dodé C, Dunkel L, Dwyer AA, Giacobini P, Hardelin JP, Juul A, Maghnie M, Pitteloud N, Prevot V, Raivio T, Tena-Sempere M, Quinton R, Young J.** Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism-pathogenesis, diagnosis and treatment. *Nat. Rev. Endocrinol.* 2015;11(9):547–564.
9. **Cangiano B, Swee DS, Quinton R, Bonomi M.** Genetics of congenital hypogonadotropic hypogonadism: peculiarities and phenotype of an oligogenic disease. *Hum. Genet.* 2021;140(1):77–111.
10. **Young J.** Approach to the male patient with congenital hypogonadotropic hypogonadism. *J. Clin. Endocrinol. Metab.* 2012;97(3):707–718.
11. **Rogol AD.** New facets of androgen replacement therapy during childhood and adolescence. *Expert Opin. Pharmacother.* 2005;6(8):1319–1336.
12. **Maione L, Pala G, Bouvattier C, Trabado S, Papadakis G, Chanson P, Bouligand J, Pitteloud N, Dwyer AA, Maghnie M, Young J.** Congenital hypogonadotropic hypogonadism/ Kallmann syndrome is associated with statural gain in both men and women: A monocentric study. *Eur. J. Endocrinol.* 2020;182(2):185–194.
13. **Cangiano B, Goggi G, Federici S, Bresesti C, Cotellessa L, Guizzardi F, Vezzoli V, Duminuco P, Persani L, Bonomi M.** Predictors of reproductive and non-reproductive outcomes of gonadotropin mediated pubertal induction in male patients with congenital hypogonadotropic hypogonadism (CHH). *J. Endocrinol. Invest.* 2021. doi:10.1007/s40618-021-01556-x.
14. **Varimo T, Miettinen PJ, Käsäkoski J, Raivio T, Hero M.** Congenital hypogonadotropic hypogonadism, functional hypogonadotropism or constitutional

- delay of growth and puberty? An analysis of a large patient series from a single tertiary center. *Hum. Reprod.* 2017;32(1):147–153.
15. **Huang CC, Lin KL, Wu CT, Jung SM, Wang CJ, Chen YC, Lo FS.** Clinical and endocrinological manifestations of childhood-onset craniopharyngioma before surgical removal: A report from one medical center in Taiwan. *Pediatr. Neonatol.* 2021;62(2):181–186.
 16. **Sbardella E, Puliani G, Feola T, Pofi R, Pirchio R, Sesti F, Verdecchia F, Gianfrilli D, Moffat D, Isidori AM, Grossman AB, Savage AM, Foresta C, Krausz C, Durante C, De Martino MC, Paoli D, Ferrigno R, Caiulo S, Minnetti M, Hasenmajer V, Pozza C, Kanakis G, Cangiano B, Tenuta M, Petrozzi A, Carlomagno F, Di Nisio A, Pallotti F, Tarsitano MG, Spaziani M, Cargnelutti F, Sabovic I, Grani G, Virili C, Cozzolino A, Stramazzo I, Filardi T, Mazzotta P.** A clinical approach to parasellar lesions in the transition age. *J. Neuroendocrinol.* 2021;33(6). doi:10.1111/jne.12995.
 17. **Kindblom JM, Lorentzon M, Norjavaara E, Hellqvist A, Nilsson S, Mellström D, Ohlsson C.** Pubertal timing predicts previous fractures and BMD in young adult men: The GOOD study. *J. Bone Miner. Res.* 2006;21(5):790–795.
 18. **Finkelstein JS, Neer RM, Biller BMK, Crawford JD, Klibanski A.** Osteopenia in Men with a History of Delayed Puberty. *N. Engl. J. Med.* 1992;326(9):600–604.
 19. **Finkelstein JS, Klibanski A, Neer RM.** A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty. *J. Clin. Endocrinol. Metab.* 1996;81(3):1152–1155.
 20. **Lubushitzky R, Front D, Iosilevsky G, Bettman L, Frenkel A, Kolodny GM,**

- Israel O.** Quantitative bone SPECT in young males with delayed puberty and hypogonadism: Implications for treatment of low bone mineral density. *J. Nucl. Med.* 1998;39(1):104–107.
21. **Almeida M, Laurent MR, Dubois V, Claessens F, O'Brien CA, Bouillon R, Vanderschueren D, Manolagas SC.** Estrogens and androgens in skeletal physiology and pathophysiology. *Physiol. Rev.* 2017;97(1):135–187.
22. **Bertelloni S, Baroncelli GI, Ferdeghini M, Perri G, Saggese G.** Normal volumetric bone mineral density and bone turnover in young men with histories of constitutional delay of puberty. *J. Clin. Endocrinol. Metab.* 1998;83(12):4280–4283.
23. **Yap F, Högler W, Briody J, Moore B, Howman-Giles R, Cowell CT.** The skeletal phenotype of men with previous constitutional delay of puberty. *J. Clin. Endocrinol. Metab.* 2004;89(9):4306–4311.
24. **De Rosa M, Paesano L, Nuzzo V, Zarrilli S, Del Puente A, Oriente P, Lupoli G.** Bone mineral density and bone markers in hypogonadotropic and hypergonadotropic hypogonadal men after prolonged testosterone treatment. *J. Endocrinol. Invest.* 2001;24(4):246–252.
25. **Laitinen EM, Hero M, Vaaralahti K, Tommiska J, Raivio T.** Bone mineral density, body composition and bone turnover in patients with congenital hypogonadotropic hypogonadism. *Int. J. Androl.* 2012;35(4):534–540.
26. **Hines M, Brook C, Conway GS.** Androgen and psychosexual development: Core gender identity, sexual orientation, and recalled childhood gender role behavior in women and men with congenital adrenal hyperplasia (CAH). *J. Sex Res.* 2004;41(1):75–81.

27. **Ristori J, Cocchetti C, Romani A, Mazzoli F, Vignozzi L, Maggi M, Fisher AD.** Brain sex differences related to gender identity development: Genes or hormones? *Int. J. Mol. Sci.* 2020;21(6). doi:10.3390/ijms21062123.
28. **Achermann JC, Hughes IA.** Pediatric Disorders of Sex Development. *Williams Textb. Endocrinol.* 2016:893–963.
29. **Swee DS, Quinton R.** Managing congenital hypogonadotropic hypogonadism: a contemporary approach directed at optimizing fertility and long-term outcomes in males. *Ther. Adv. Endocrinol. Metab.* 2019;10:2042018819826889.
30. **Dwyer AA, Quinton R, Morin D, Pitteloud N.** Identifying the unmet health needs of patients with congenital hypogonadotropic hypogonadism using a web-based needs assessment: Implications for online interventions and peer-to-peer support. *Orphanet J. Rare Dis.* 2014;9(1). doi:10.1186/1750-1172-9-83.
31. **Dwyer AA, Quinton R, Pitteloud N, Morin D.** Psychosexual Development in Men with Congenital Hypogonadotropic Hypogonadism on Long-Term Treatment: A Mixed Methods Study. *Sex. Med.* 2015;3(1):32–41.
32. **Nabhan Z, Eugster E.** Hormone replacement therapy in children with hypogonadotropic hypogonadism: Where do we stand? *Endocr. Pract.* 2013;19(6):968–971.
33. **Sukumar SP, Bhansali A, Sachdeva N, Ahuja CK, Gorski U, Jarial KDS, Walia R.** Diagnostic utility of testosterone priming prior to dynamic tests to differentiate constitutional delay in puberty from isolated hypogonadotropic hypogonadism. *Clin. Endocrinol. (Oxf).* 2017;86(5):717–724.
34. **Rohayem J, Hauffa BP, Zacharin M, Kliesch S, Zitzmann M, Wüsthof A, Tittel**

- B, Tittel B, Morlot M, Vorhoff W, Müller-Rossberg E, Müller-Rossberg E, Wagner V, Wagner V, Wagner V, Konrad K, Salzgeber K, Fricke-Otto S, Wölfle J, Willig P, Karges B, Lankes E, Droste M, Richter-Unruh A, Liesenkötter KP, Hübner A, Zichner S, Welzel M, Dunstheimer D, Potelajew U, Heger S, Hammer E, Oevering R, Schmidt S, Nieschlag E.** Testicular growth and spermatogenesis: new goals for pubertal hormone replacement in boys with hypogonadotropic hypogonadism? -a multicentre prospective study of hCG/rFSH treatment outcomes during adolescence-. *Clin. Endocrinol. (Oxf)*. 2017;86(1):75–87.
35. **Zacharin M, Sabin MA, Nair V V., Dagabdhao P.** Addition of recombinant follicle-stimulating hormone to human chorionic gonadotropin treatment in adolescents and young adults with hypogonadotropic hypogonadism promotes normal testicular growth and may promote early spermatogenesis. *Fertil. Steril*. 2012;98(4):836–842.
36. **Barrio R, De Luis D, Alonso M, Lamas A, Moreno JC.** Induction of puberty with human chorionic gonadotropin and follicle-stimulating hormone in adolescent males with hypogonadotropic hypogonadism. *Fertil. Steril*. 1999;71(2):244–248.
37. **Liu PY, Gebiski VJ, Turner L, Conway AJ, Wishart SM, Handelsman DJ.** Predicting pregnancy and spermatogenesis by survival analysis during gonadotrophin treatment of gonadotrophin-deficient infertile men. *Hum. Reprod*. 2002;17(3):625–633.
38. **Rohayem J, Zitzmann M, Laurentino S, Kliesch S, Nieschlag E, Holterhus PM, Kulle A.** The role of gonadotropins in testicular and adrenal androgen biosynthesis pathways—Insights from males with congenital hypogonadotropic hypogonadism on hCG/rFSH and on testosterone replacement. *Clin. Endocrinol. (Oxf)*. 2021;94(1):90–101.

39. **Liu PY, Baker HWG, Jayadev V, Zacharin M, Conway AJ, Handelsman DJ.** Induction of spermatogenesis and fertility during gonadotropin treatment of Gonadotropin-Deficient infertile men: Predictors of fertility outcome. *J. Clin. Endocrinol. Metab.* 2009;94(3):801–808.
40. **Shah R, Patil V, Sarathi V, Lila AR, Zacharin M, Krishnappa B, Sehemby M, Jaiswal SK, Jadhav PL, Ramteke-Jadhav S, Shah N, Bandgar T.** Prior testosterone replacement therapy may impact spermatogenic response to combined gonadotropin therapy in severe congenital hypogonadotropic hypogonadism. *Pituitary* 2021;24(3):326–333.
41. **Rastrelli G, Corona G, Mannucci E, Maggi M.** Factors affecting spermatogenesis upon gonadotropin-replacement therapy: a meta-analytic study. *Andrology* 2014;2(6):794–808.
42. **Delemarre-Van De Waal HA.** Application of gonadotropin releasing hormone in hypogonadotropic hypogonadism - Diagnostic and therapeutic aspects. In: *European Journal of Endocrinology, Supplement*. Vol 151. Eur J Endocrinol; 2004. doi:10.1530/eje.0.151u089.
43. **Schopohl J.** Pulsatile gonadotrophin releasing hormone versus gonadotrophin treatment of hypothalamic hypogonadism in males. *Hum. Reprod.* 1993;8:175–179.
44. **Gong C, Liu Y, Qin M, Wu D, Wang X.** Pulsatile GnRH is superior to HCG in therapeutic efficacy in adolescent boys with hypogonadotropic hypogonadism. *J. Clin. Endocrinol. Metab.* 2015;100(7):2793–2799.
45. **Liu L, Banks SM, Barnes KM, Sherins RJ.** Two-year comparison of testicular responses to pulsatile gonadotropin-releasing hormone and exogenous gonadotropins

- from the inception of therapy in men with isolated hypogonadotropic hypogonadism. *J. Clin. Endocrinol. Metab.* 1988;67(6):1140–1145.
46. **Han TS, Bouloux PMG.** What is the optimal therapy for young males with hypogonadotropic hypogonadism? *Clin. Endocrinol. (Oxf).* 2010;72(6):731–737.
47. **Mason KA, Schoelwer MJ, Rogol AD.** Androgens during infancy, childhood, and adolescence: Physiology and use in clinical practice. *Endocr. Rev.* 2020;41(3):421–456.
48. **Drobac S, Rubin K, Rogol AD, Rosenfield RL.** A Workshop on pubertal hormone replacement options in the United States. *J. Pediatr. Endocrinol. Metab.* 2006;19(1):55–64.
49. **Hamza RT, Deeb A, Al Saffar H, Alani SH, Habeb A.** Timing and regimen of puberty induction in children with hypogonadism: A survey on the practice in Arab countries. *J. Pediatr. Endocrinol. Metab.* 2020;33(9):1197–1202.
50. **Bertelloni S, Baroncelli GI, Garofalo P, Cianfarani S.** Androgen therapy in hypogonadal adolescent males. *Horm. Res. Paediatr.* 2010;74(4):292–296.
51. **Lucas-Herald AK, Mason E, Beaumont P, Mason A, Shaikh MG, Wong SC, Ahmed SF.** Single-Centre Experience of Testosterone Therapy for Boys with Hypogonadism. *Horm. Res. Paediatr.* 2018;90(2):123–127.
52. **Delemarre EM, Felius B, Delemarre-Van De Waal HA.** Inducing puberty. In: *European Journal of Endocrinology.* Vol 159.; 2008. doi:10.1530/EJE-08-0314.
53. **Gooren LJG, Bunck MCM.** Androgen replacement therapy: Present and future. *Drugs* 2004;64(17):1861–1891.

54. **Harle L, Basaria S, Dobs AS.** Nebido: A long-acting injectable testosterone for the treatment of male hypogonadism. *Expert Opin. Pharmacother.* 2005;6(10):1751–1759.
55. **Giagulli VA, Triggiani V, Carbone MD, Corona G, Tafaro E, Licchelli B, Guastamacchia E.** The Role of Long-Acting Parenteral Testosterone Undecanoate Compound in the Induction of Secondary Sexual Characteristics in Males with Hypogonadotropic Hypogonadism. *J. Sex. Med.* 2011;8(12):3471–3478.
56. **Rogol AD, Swerdloff RS, Reiter EO, Ross JL, Zumbrennen TL, Pratt GA, Brennan JJ, Benesh J, Kan-Dobrosky N, Miller MG.** A multicenter, open-label, observational study of testosterone gel (1%) in the treatment of adolescent boys with klinefelter syndrome or anorchia. *J. Adolesc. Heal.* 2014;54(1):20–25.
57. **Srinivas-Shankar U, Sharma D.** Testosterone treatment in elderly men. *Adv. Ther.* 2009;26(1):25–39.
58. **Köhn FM, Schill WB.** A new oral testosterone undecanoate formulation. *World J. Urol.* 2003;21(5):311–315.
59. **Albanese A, Kewley GD, Long A, Pearl KN, Robins DG, Stanhope R.** Oral treatment for constitutional delay of growth and puberty in boys: A randomised trial of an anabolic steroid or testosterone undecanoate. *Arch. Dis. Child.* 1994;71(4):315–317.
60. **Butler GE, Sellar RE, Walker RF, Hendry M, Kelnar CJH, Wu FCW.** Oral testosterone undecanoate in the management of delayed puberty in boys: Pharmacokinetics and effects on sexual maturation and growth. *J. Clin. Endocrinol. Metab.* 1992;75(1):37–44.
61. **Brown DC, Butler GE, Kelnar CJH, Wu FCW.** A double blind, placebo controlled study of the effects of low dose testosterone undecanoate on the growth of small for

- age, prepubertal boys. *Arch. Dis. Child.* 1995;73(2):131–135.
62. **Gregory JW, Greene SA, Thompson J, Scrlmgeour CM, Rennle MJ.** Effects of oral testosterone undecanoate on growth, body composition, strength and energy expenditure of adolescent boys. *Clin. Endocrinol. (Oxf).* 1992;37(3):207–213.
63. **Schmidt H, Knorr D, Schwarz HP.** Oral testosterone undecanoate for the induction of puberty in anorchid boys [5]. *Arch. Dis. Child.* 1998;78(4):397.
64. **Weil J, Bidlingmaier F, Butenandt O, Sippell WG, Baumgartner W, Knorr D.** Treatment of anorchia with oral testosterone undecanoate: Pharmacodynamics and clinical effectiveness. *Acta Endocrinol. (Copenh).* 1980;95(2):244–250.
65. **Zacharin MR, Warne GL.** Treatment of hypogonadal adolescent boys with long acting subcutaneous testosterone pellets. *Arch. Dis. Child.* 1997;76(6):495–499.
66. **Basaria S, Lakshman KM.** Safety and efficacy of testosterone gel in the treatment of male hypogonadism. *Clin. Interv. Aging* 2009;4:397.
67. **Chioma L, Papucci G, Fintini D, Cappa M.** Use of testosterone gel compared to intramuscular formulation for puberty induction in males with constitutional delay of growth and puberty: a preliminary study. *J. Endocrinol. Invest.* 2018;41(2):259–263.
68. **Contreras MF, Raisingani M, Prasad K, Franklin B, Shah B.** Transdermal testosterone gel for induction and continuation of puberty in adolescent boys with hepatic dysfunction. *J. Pediatr. Endocrinol. Metab.* 2017;30(1):105–109.
69. **Santhakumar A, Miller M, Quinton R.** Pubertal induction in adult males with isolated hypogonadotropic hypogonadism using long-acting intramuscular testosterone undecanoate 1-g depot (Nebido®). *Clin. Endocrinol. (Oxf).* 2014;80(1):155–157.

70. **Pazderska A, Mamoojee Y, Artham S, Miller M, Ball SG, Cheetham T, Quinton R.** Safety and tolerability of one-year intramuscular testosterone regime to induce puberty in older men with CHH. *Endocr. Connect.* 2018;7(1):133–138.
71. **Zacharin M.** Disorders of puberty: Pharmacotherapeutic strategies for management. In: *Handbook of Experimental Pharmacology*. Vol 261. Handb Exp Pharmacol; 2020:507–538.
72. **Swerdloff RS, Dudley RE.** A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men. *Ther. Adv. Urol.* 2020;12. doi:10.1177/1756287220937232.
73. **Swerdloff RS, Wang C, White WB, Kaminetsky J, Gittelman MC, Longstreth JA, Dudley RE, Danoff TM.** A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. *J. Clin. Endocrinol. Metab.* 2020;105(8). doi:10.1210/clinem/dgaa238.
74. **Kaminetsky J, Jaffe JS, Swerdloff RS.** Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study. *Sex. Med.* 2015;3(4):269–279.
75. **Kaminetsky JC, Mccullough A, Hwang K, Jaffe JS, Wang C, Swerdloff RS.** A 52-week study of dose adjusted subcutaneous testosterone enanthate in oil self-administered via disposable auto-injector. *J. Urol.* 2019;201(3):587–594.
76. **Choi EJ, Xu P, El-Khatib FM, Kavoussi PK, Yafi FA.** Post-market safety and efficacy profile of subcutaneous testosterone enanthate-autoinjector: a cohort analysis. *Int. J. Impot. Res.* 2021. doi:10.1038/s41443-021-00435-6.
77. **Gittelman M, Jaffe JS, Kaminetsky JC.** Safety of a New Subcutaneous Testosterone

- Enanthate Auto-Injector: Results of a 26-Week Study. *J. Sex. Med.* 2019;16(11):1741–1748.
78. **Spratt DI, Stewart II, Savage C, Craig W, Spack NP, Chandler DW, Spratt L V., Eimicke T, Olshan JS.** Subcutaneous injection of testosterone is an effective and preferred alternative to intramuscular injection: Demonstration in female-to-male transgender patients. *J. Clin. Endocrinol. Metab.* 2017;102(7):2349–2355.
79. **Olson J, Schragger SM, Clark LF, Dunlap SL, Belzer M.** Subcutaneous testosterone: An effective delivery mechanism for masculinizing young transgender men. *LGBT Heal.* 2014;1(3):165–167.
80. **Olson-Kennedy J, Okonta V, Clark LF, Belzer M.** Physiologic Response to Gender-Affirming Hormones Among Transgender Youth. *J. Adolesc. Heal.* 2018;62(4):397–401.
81. **Jarin J, Pine-Twaddell E, Trotman G, Stevens J, Conard LA, Tefera E, Gomez-Lobo V.** Cross-sex hormones and metabolic parameters in adolescents with gender dysphoria. *Pediatrics* 2017;139(5). doi:10.1542/peds.2016-3173.
82. **Stancampiano MR, Lucas-Herald AK, Russo G, Rogol AD, Ahmed SF.** Testosterone Therapy in Adolescent Boys: The Need for a Structured Approach. *Horm. Res. Paediatr.* 2020;92(4):215–228.
83. **Federici S, Goggi G, Quinton R, Giovanelli L, Persani L, Cangiano B, Bonomi M.** Data from: New and consolidated therapeutic options for pubertal induction in hypogonadism: in-depth review of the literature (Supplementary Tables). Zenodo Digital Repository. Deposited 15 October 2021. doi:10.5281/zenodo.5572710.
84. **Raivio T, Wikström AM, Dunkel L.** Treatment of gonadotropin-deficient boys with

- recombinant human FSH: Long-term observation and outcome. *Eur. J. Endocrinol.* 2007;156(1):105–111.
85. **Dwyer AA, Sykiotis GP, Hayes FJ, Boepple PA, Lee H, Loughlin KR, Dym M, Sluss PM, Crowley WF, Pitteloud N.** Trial of recombinant follicle-stimulating hormone pretreatment for GnRH-induced fertility in patients with congenital hypogonadotropic hypogonadism. *J. Clin. Endocrinol. Metab.* 2013;98(11). doi:10.1210/jc.2013-2518.
86. **Sinisi AA, Esposito D, Bellastella G, Maione L, Palumbo V, Gandini L, Lombardo F, De Bellis A, Lenzi A, Bellastella A.** Efficacy of recombinant human follicle stimulating hormone at low doses in inducing spermatogenesis and fertility in hypogonadotropic hypogonadism. *J. Endocrinol. Invest.* 2010;33(9):618–623.
87. **Trinchard-Lugan I, Khan A, Porchet HC, Munafò A.** Pharmacokinetics and pharmacodynamics of recombinant human chorionic gonadotrophin in healthy male and female volunteers. *Reprod. Biomed. Online* 2002;4(2):106–115.
88. **Boeri L, Capogrosso P, Salonia A.** Gonadotropin Treatment for the Male Hypogonadotropic Hypogonadism. *Curr. Pharm. Des.* 2020;27(24):2775–2783.
89. **Burriss AS, Rodbard HW, Winters SJ, Sherins RJ.** Gonadotropin therapy in men with isolated hypogonadotropic hypogonadism: The response to human chorionic gonadotropin is predicted by initial testicular size. *J. Clin. Endocrinol. Metab.* 1988;66(6):1144–1151.
90. **VICARI E, MONGIOÌ A, CALOGERO AE, MONCADA ML, SIDOTI G, POLOSA P, D'AGATA R.** Therapy with human chorionic gonadotrophin alone induces spermatogenesis in men with isolated hypogonadotropic hypogonadism-

long- term follow- up. *Int. J. Androl.* 1992;15(4):320–329.

91. **Zhang M, Tong G, Liu Y, Mu Y, Weng J, Xue Y, Luo Z, Xue Y, Shi L, Wu X, Sun S, Zhu Y, Cao Y, Zhang J, Huang H, Niu B, Li H, Guo Q, Gao Y, Li Z, Ning G, Zhu D, Li X.** Sequential versus continual purified urinary FSH/hCG in men with idiopathic hypogonadotropic hypogonadism. *J. Clin. Endocrinol. Metab.* 2015;100(6):2449–2455.
92. **De Sanctis V, Vullo C, Katz M, Wonke B, Nannetti C, Bagni B.** Induction of spermatogenesis in thalassaemia. *Fertil. Steril.* 1988;50(6):969–975.
93. **Bouloux P, Warne DW, Loumaye E.** Efficacy and safety of recombinant human follicle-stimulating hormone in men with isolated hypogonadotropic hypogonadism. *Fertil. Steril.* 2002;77(2):270–273.
94. **Bouloux PMG, Nieschlag E, Burger HG, Skakkebaek NE, Wu FCW, Handelsman DJ, Baker GHW, Ochsenkuehn R, Syska A, McLachlan RI, Giwercman A, Conway AJ, Turner L, Van Kuijk JHM, Voortman G.** Induction of Spermatogenesis by Recombinant Follicle-Stimulating Hormone (Puregon) in Hypogonadotropic Azoospermic Men Who Failed to Respond to Human Chorionic Gonadotropin Alone. *J. Androl.* 2003;24(4):604–611.
95. **Matsumoto AM, Snyder PJ, Bhasin S, Martin K, Weber T, Winters S, Spratt D, Brentzel J, O’Dea L.** Stimulation of spermatogenesis with recombinant human follicle-stimulating hormone (follitropin alfa; GONAL-f®): long-term treatment in azoospermic men with hypogonadotropic hypogonadism. *Fertil. Steril.* 2009;92(3):979–990.
96. **Sinisi AA, Esposito D, Maione L, Quinto MC, Visconti D, De Bellis A, Bellastella**

- A, Conzo G, Bellastella G.** Seminal anti-Müllerian hormone level is a marker of spermatogenic response during long-term gonadotropin therapy in male hypogonadotropic hypogonadism. *Hum. Reprod.* 2008;23(5):1029–1034.
97. **Orth JM.** The role of follicle-stimulating hormone in controlling sertoli cell proliferation in testes of fetal rats. *Endocrinology* 1984;115(4):1248–1255.
98. **Ramaswamy S, Marshall GR, Mcneilly AS, Plant TM.** Dynamics of the Follicle-Stimulating Hormone (FSH)-inhibin B feedback loop and its role in regulating spermatogenesis in the adult male rhesus monkey (*Macaca mulatta*) as revealed by unilateral orchidectomy. *Endocrinology* 2000;141(1):18–27.
99. **Young J, Chanson P, Salenave S, Noël M, Brailly S, O’Flaherty M, Schaison G, Rey R.** Testicular anti-Müllerian hormone secretion is stimulated by recombinant human FSH in patients with congenital hypogonadotropic hypogonadism. *J. Clin. Endocrinol. Metab.* 2005;90(2):724–728.
100. **Depenbusch M, von Eckardstein S, Simoni M, Nieschlag E.** Maintenance of spermatogenesis in hypogonadotropic hypogonadal men with human chorionic gonadotropin alone. *Eur. J. Endocrinol.* 2002;147(5):617–624.
101. **Johnsen SG.** Maintenance of spermatogenesis induced by HMG treatment by means of continuous HCG treatment in hypogonadotrophic men. *Acta Endocrinol. (Copenh).* 1978;89(4):763–769.
102. **Saal W, Happ J, Cordes U, Baum RP, Schmidt M.** Subcutaneous gonadotropin therapy in male patients with hypogonadotropic hypogonadism. *Fertil. Steril.* 1991;56(2):319–324.
103. **Dwyer AA, Jayasena CN, Quinton R.** Congenital hypogonadotropic hypogonadism:

- Implications of absent mini-puberty. *Minerva Endocrinol.* 2016;41(2):188–195.
104. **Bouvattier C, Maione L, Bouligand J, Dodé C, Guiochon-Mantel A, Young J.** Neonatal gonadotropin therapy in male congenital hypogonadotropic hypogonadism. *Nat. Rev. Endocrinol.* 2012;8(3):172–182.
105. **Main KM, Schmidt IM, Toppari J, Skakkebaek NE.** Early postnatal treatment of hypogonadotropic hypogonadism with recombinant human FSH and LH. *Eur. J. Endocrinol.* 2002;146(1):75–79.
106. **Bougnères P, François M, Pantalone L, Rodrigue D, Bouvattier C, Demesteere E, Roger D, Lahlou N.** Effects of an early postnatal treatment of hypogonadotropic hypogonadism with a continuous subcutaneous infusion of recombinant follicle-stimulating hormone and luteinizing hormone. *J. Clin. Endocrinol. Metab.* 2008;93(6):2202–2205.
107. **Sarfati J, Bouvattier C, Bry-Gaillard H, Cartes A, Bouligand J, Young J.** Kallmann syndrome with FGFR1 and KAL1 mutations detected during fetal life. *Orphanet J. Rare Dis.* 2015;10(1). doi:10.1186/s13023-015-0287-9.
108. **Lambert A-S, Bougnères P.** Growth and descent of the testes in infants with hypogonadotropic hypogonadism receiving subcutaneous gonadotropin infusion. *Int. J. Pediatr. Endocrinol.* 2016;2016(1). doi:10.1186/s13633-016-0031-9.
109. **Stoupa A, Samara-Boustani D, Flechtner I, Pinto G, Jourdon I, González-Briceño L, Bidet M, Laborde K, Chevenne D, Millischer AE, Lottmann H, Blanc T, Aigrain Y, Polak M, Beltrand J.** Efficacy and Safety of Continuous Subcutaneous Infusion of Recombinant Human Gonadotropins for Congenital Micropenis during Early Infancy. *Horm. Res. Paediatr.* 2017;87(2):103–110.

110. **Kohva E, Huopio H, Hietamäki J, Hero M, Miettinen PJ, Raivio T.** Treatment of gonadotropin deficiency during the first year of life: long-term observation and outcome in five boys. *Hum. Reprod.* 2019;34(5):863–871.
111. **Ankarberg-Lindgren C, Dahlgren J, Andersson MX.** High-sensitivity quantification of serum androstenedione, testosterone, dihydrotestosterone, estrone and estradiol by gas chromatography–tandem mass spectrometry with sex- and puberty-specific reference intervals. *J. Steroid Biochem. Mol. Biol.* 2018;183:116–124.
112. **Weber DR, Boyce A, Gordon C, Högl W, Kecskemethy HH, Misra M, Swolin-Eide D, Tebben P, Ward LM, Wasserman H, Shuhart C, Zemel BS.** The Utility of DXA Assessment at the Forearm, Proximal Femur, and Lateral Distal Femur, and Vertebral Fracture Assessment in the Pediatric Population: 2019 ISCD Official Position. *J. Clin. Densitom.* 2019;22(4):567–589.
113. **Goede J, Hack WWM, Sijstermans K, Van Der Voort-Doedens LM, Van Der Ploeg T, Meij-De Vries A, Delemarre-Van De Waal HA.** Normative values for testicular volume measured by ultrasonography in a normal population from infancy to adolescence. *Horm. Res. Paediatr.* 2011;76(1):56–64.
114. **Sidhoum VF, Chan YM, Lippincott MF, Balasubramanian R, Quinton R, Plummer L, Dwyer A, Pitteloud N, Hayes FJ, Hall JE, Martin KA, Boepple PA, Seminara SB.** Reversal and relapse of hypogonadotropic hypogonadism: Resilience and fragility of the reproductive neuroendocrine system. *J. Clin. Endocrinol. Metab.* 2014;99(3):861–870.
115. **Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA.** Testosterone Therapy in Men

- with Hypogonadism: An Endocrine Society. *J. Clin. Endocrinol. Metab.* 2018;103(5):1715–1744.
116. **Schoemaker J, Van Kessel H, Simons AHM, Korsen TJM.** Induction of first cycles in primary hypothalamic amenorrhea with pulsatile luteinizing hormone-releasing hormone: A mirror of female pubertal development. *Fertil. Steril.* 1987;48(2):204–212.
117. **Yasmin E, Davies M, Conway G, Balen AH.** British Fertility Society: “Ovulation induction in WHO Type 1 anovulation: Guidelines for practice” Produced on behalf of the BFS Policy and Practice Committee. *Hum. Fertil.* 2013;16(4):228–234.
118. **Huseyin K, Berk B, Tolga K, Eser O, Ali G, Murat A.** Management of ovulation induction and intrauterine insemination in infertile patients with hypogonadotropic hypogonadism. *J. Gynecol. Obstet. Hum. Reprod.* 2019;48(10):833–838.
119. **Szeliga A, Podfigurna A, Bala G, Meczekalski B.** Kisspeptin and neurokinin B analogs use in gynecological endocrinology: where do we stand? *J. Endocrinol. Invest.* 2020;43(5):555–561.
120. **Young J, George JT, Tello JA, Francou B, Bouligand J, Guiochon-Mantel A, Brailly-Tabard S, Anderson RA, Millar RP.** Kisspeptin restores pulsatile LH secretion in patients with neurokinin B signaling deficiencies: Physiological, pathophysiological and therapeutic implications. *Neuroendocrinology* 2013;97(2):193–202.
121. **Alonso LC, Rosenfield RL.** Oestrogens and puberty. *Best Pract. Res. Clin. Endocrinol. Metab.* 2002;16(1):13–30.
122. **Vinogradova Y, Coupland C, Hippisley-Cox J.** Use of hormone replacement therapy

- and risk of venous thromboembolism: Nested case-control studies using the QResearch and CPRD databases. *BMJ* 2019;364. doi:10.1136/bmj.k4810.
123. **Smith NL, Blondon M, Wiggins KL, Harrington LB, Van Hylckama Vlieg A, Floyd JS, Hwang M, Bis JC, McKnight B, Rice KM, Lumley T, Rosendaal FR, Heckbert SR, Psaty BM.** Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. *JAMA Intern. Med.* 2014;174(1):25–31.
124. **Odonnell RL, Warner P, Lee RJ, Walker J, Bath LE, Kelnar CJ, Wallace WHB, Critchley HOD.** Physiological sex steroid replacement in premature ovarian failure: Randomized crossover trial of effect on uterine volume, endometrial thickness and blood flow, compared with a standard regimen. *Hum. Reprod.* 2012;27(4):1130–1138.
125. **Asscheman H, Giltay EJ, Megens JAJ, De Ronde W, Van Trotsenburg MAA, Gooren LJG.** A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. *Eur. J. Endocrinol.* 2011;164(4):635–642.
126. **Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, Køber L, Jensen JEB.** Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: Randomised trial. *BMJ* 2012;345(7881). doi:10.1136/bmj.e6409.
127. **Davenport ML.** Approach to the patient with Turner syndrome. *J. Clin. Endocrinol. Metab.* 2010;95(4):1487–1495.
128. **Matthews D, Bath L, Högler W, Mason A, Smyth A, Skae M.** Hormone supplementation for pubertal induction in girls. *Arch. Dis. Child.* 2017;102(10):975–980.

129. **Swee DS, Javaid U, Quinton R.** Estrogen Replacement in Young Hypogonadal Women—Transferrable Lessons From the Literature Related to the Care of Young Women With Premature Ovarian Failure and Transgender Women. *Front. Endocrinol. (Lausanne)*. 2019;10:685.
130. **Kuhl H.** Pharmacology of estrogens and progestogens: Influence of different routes of administration. *Climacteric* 2005;8(SUPPL. 1):3–63.
131. **Mohammed K, Dabrh AMA, Benkhadra K, Al Nofal A, Carranza Leon BG, Prokop LJ, Montori VM, Faubion SS, Murad MH.** Oral vs transdermal estrogen therapy and vascular events: A systematic review and meta-analysis. *J. Clin. Endocrinol. Metab.* 2015;100(11):4012–4020.
132. **Canonico M, Carcaillon L, Plu-Bureau G, Oger E, Singh-Manoux A, Tubert-Bitter P, Elbaz A, Scarabin PY.** Postmenopausal hormone therapy and risk of stroke: Impact of the route of estrogen administration and type of progestogen. *Stroke* 2016;47(7):1734–1741.
133. **Renoux C, Dell’Aniello S, Garbe E, Suissa S.** Transdermal and oral hormone replacement therapy and the risk of stroke: A nested case-control study. *BMJ* 2010;341(7763):83.
134. **Sweetland S, Beral V, Balkwill A, Liu B, Benson VS, Canonico M, Green J, Reeves GK, Abbott S, Allen N, Armstrong M, Banks E, Beral V, Black J, Brown A, Bull D, Cairns B, Callaghan K, Canfell K, Canoy D, Chivenga J, Crossley B, Crowe F, Ewart D, Ewart S, Fletcher L, Gathani T, Gerrard L, Goodill A, Guiver L, Hilton E, Kan SW, Keene C, Kirichek O, Kroll M, Langston N, Lingard I, Luque MJ, Pank L, Pirie K, Roddam A, Shaw K, Sherman E, Sherry-Starmer E,**

- Strange H, Timadger A, Tipper S, Travis R, Wang X, Watson J, Wright L, Yang T, Young H.** Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. *J. Thromb. Haemost.* 2012;10(11):2277–2286.
135. **Modena MG, Sismondi P, Mueck AO, Kuttann F, De Lignières B, Verhaeghe J, Foidart JM, Caufriez A, Genazzani AR.** New evidence regarding hormone replacement therapies is urgently required: Transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. *Maturitas* 2005;52(1):1–10.
136. **Scarabin PY, Oger E, Plu-Bureau G.** Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. *Lancet* 2003;362(9382):428–432.
137. **Ichikawa J, Sumino H, Ichikawa S, Ozaki M.** Different Effects of Transdermal and Oral Hormone Replacement Therapy on the Renin-Angiotensin System, Plasma Bradykinin Level, and Blood Pressure of Normotensive Postmenopausal Women. *Am. J. Hypertens.* 2006;19(7):744–749.
138. **Yilmazer M, Fenkci V, Fenkci S, Sonmezer M, Aktepe O, Altindis M, Kurtay G.** Hormone replacement therapy, C-reactive protein, and fibrinogen in healthy postmenopausal women. *Maturitas* 2003;46(4):245–253.
139. **O’Sullivan AJ, Crampton LJ, Freund J, Ho KKY.** The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. *J. Clin. Invest.* 1998;102(5):1035–1040.
140. **Chu MC, Cospes P, Nakhuda GS, Lobo RA.** A comparison of oral and transdermal

- short-term estrogen therapy in postmenopausal women with metabolic syndrome. *Fertil. Steril.* 2006;86(6):1669–1675.
141. **Phelan N, Conway SH, Llahana S, Conway GS.** Quantification of the adverse effect of ethinylestradiol containing oral contraceptive pills when used in conjunction with growth hormone replacement in routine practice. *Clin. Endocrinol. (Oxf).* 2012;76(5):729–733.
142. **Isotton AL, Wender MCO, Casagrande A, Rollin G, Czepielewski MA.** Effects of oral and transdermal estrogen on IGF1, IGFBP3, IGFBP1, serum lipids, and glucose in patients with hypopituitarism during GH treatment: A randomized study. *Eur. J. Endocrinol.* 2012;166(2):207–213.
143. **Seal LJ, Franklin S, Richards C, Shishkareva A, Sinclair C, Barrett J.** Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens. *J. Clin. Endocrinol. Metab.* 2012;97(12):4422–4428.
144. **Shah S, Forghani N, Durham E, Neely EK.** A randomized trial of transdermal and oral estrogen therapy in adolescent girls with hypogonadism. *Int. J. Pediatr. Endocrinol.* 2014;2014(1). doi:10.1186/1687-9856-2014-12.
145. **Nabhan ZM, DiMeglio LA, Qi R, Perkins SM, Eugster EA.** Conjugated oral versus transdermal estrogen replacement in girls with Turner syndrome: A pilot comparative study. *J. Clin. Endocrinol. Metab.* 2009;94(6):2009–2014.
146. **Mauras N, Shulman D, Hsiang HY, Balagopal P, Welch S.** Metabolic effects of oral versus transdermal estrogen in growth hormone-treated girls with Turner syndrome. *J. Clin. Endocrinol. Metab.* 2007;92(11):4154–4160.

147. **Torres-Santiago L, Mericq V, Taboada M, Unanue N, Klein KO, Singh R, Hossain J, Santen RJ, Ross JL, Mauras N.** Metabolic effects of oral versus transdermal 17 β -estradiol (E 2): A randomized clinical trial in girls with turner syndrome. *J. Clin. Endocrinol. Metab.* 2013;98(7):2716–2724.
148. **Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu JK, Eggena P, Hershman JM, Alkjaersig NK, Fletcher AP, Judd HL.** Biologic Effects of Transdermal Estradiol. *N. Engl. J. Med.* 1986;314(25):1615–1620.
149. **Taboada M, Santen R, Lima J, Hossain J, Singh R, Klein KO, Mauras N.** Pharmacokinetics and pharmacodynamics of oral and transdermal 17 β estradiol in girls with Turner syndrome. *J. Clin. Endocrinol. Metab.* 2011;96(11):3502–3510.
150. **Mauras N, Torres-Santiago L, Santen R, Mericq V, Ross J, Colon-Otero G, Damaso L, Hossain J, Wang Q, Mesaros C, Blair IA.** Impact of route of administration on genotoxic oestrogens concentrations using oral vs transdermal oestradiol in girls with Turner syndrome. *Clin. Endocrinol. (Oxf).* 2019;90(1):155–161.
151. **Zaiem F, Alahdab F, Al Nofal A, Murad MH, Javed A.** Oral Versus Transdermal Estrogen in Turner Syndrome: a Systematic Review and Meta-Analysis. *Endocr. Pract.* 2017;23(4):408–421.
152. **Piippo S, Lenko H, Kainulainen P, Sipilä I.** Use of percutaneous estrogen gel for induction of puberty in girls with Turner syndrome. *J. Clin. Endocrinol. Metab.* 2004;89(7):3241–3247.
153. **Raivio T, Miettinen PJ.** Constitutional delay of puberty versus congenital hypogonadotropic hypogonadism: Genetics, management and updates. *Best Pract. Res.*

Clin. Endocrinol. Metab. 2019;33(3). doi:10.1016/j.beem.2019.101316.

154. **Gravholt CH, Andersen NH, Conway GS, Dekkers OM, Geffner ME, Klein KO, Lin AE, Mauras N, Quigley CA, Rubin K, Sandberg DE, Sas TCJ, Silberbach M, Söderström-Anttila V, Stochholm K, Van Alfen-Van DerVelden JA, Woelfle J, Backeljauw PF, Bamba V, Bonfig NB, Braverman AC, Breech LL, Brickman WJ, Brown NM, Bryant N, Cernich J, Chernausek S, Christin-Maitre S, Corathers SD, Crawford A, Crenshaw ML, Davenport ML, De Backer J, Eagle K, Gawlik A, Gutmark-Little I, Hay D, Hiratzka L, Hong DS, Hovatta O, Hulcrantz M, Johnson WH, Kanaka-Gantenbein C, Karnis MF, Knickmeyer RC, Kristrøm B, Lajiness-O'Neill RR, Landin-Wilhelmsen K, Law JR, Lippe B, Lopez L, Mawson L, Mazzanti L, Mortensen KH, Popovic J, Prakash S, Ranallo KC, Rappold GA, Roos-Hesselink J, Rosenfield R, Ross J, Roulot-Marullo D, Saidi A, Santen RJ, Scurlock CC, Sheanon NM, Smyth A, Van Hagen IM, Verlinde F, Wasniewska M, Young LT.** Clinical practice guidelines for the care of girls and women with Turner syndrome: Proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. *Eur. J. Endocrinol.* 2017;177(3):G1–G70.
155. **Gompel A.** Micronized progesterone and its impact on the endometrium and breast vs. progestogens. *Climacteric* 2012;15(SUPPL.1):18–25.
156. **Stute P, Neulen J, Wildt L.** The impact of micronized progesterone on the endometrium: a systematic review. *Climacteric* 2016;19(4):316–328.
157. **Stute P, Wildt L, Neulen J.** The impact of micronized progesterone on breast cancer risk: a systematic review. *Climacteric* 2018;21(2):111–122.
158. **Casanova G, Spritzer PM.** Effects of micronized progesterone added to non-oral

- estradiol on lipids and cardiovascular risk factors in early postmenopause: A clinical trial. *Lipids Health Dis.* 2012;11. doi:10.1186/1476-511X-11-133.
159. **Levine H, Watson N.** Comparison of the pharmacokinetics of Crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women. *Fertil. Steril.* 2000;73(3):516–521.
160. **Davey DA.** Menopausal hormone therapy: a better and safer future. *Climacteric* 2018;21(5):454–461.
161. **Stanczyk FZ, Bhavnani BR.** Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: Is it safe? *J. Steroid Biochem. Mol. Biol.* 2014;142:30–38.
162. **Stanczyk FZ, Hapgood JP, Winer S, Mishell DR.** Progestogens used in postmenopausal hormone therapy: Differences in their pharmacological properties, intracellular actions, and clinical effects. *Endocr. Rev.* 2013;34(2):171–208.
163. **Ankarberg-Lindgren C, Elfving M, Wikland KA, Norjavaara E.** Nocturnal application of transdermal estradiol patches produces levels of estradiol that mimic those seen at the onset of spontaneous puberty in girls. *J. Clin. Endocrinol. Metab.* 2001;86(7):3039–3044.
164. **Gawlik AM, Hankus M, Szeliga K, Antosz A, Gawlik T, Soltysik K, Drosdzol-Cop A, Wilk K, Kudela G, Koszutski T, Malecka-Tendera E.** Late-onset puberty induction by transdermal estrogen in Turner syndrome girls-A longitudinal study. *Front. Endocrinol. (Lausanne).* 2018;9(FEB):23.
165. **Bannink EMN, Van Sassen C, Van Buuren S, De Jong FH, Lequin M, Mulder PGH, De Muinck Keizer-Schrama SMPF.** Puberty induction in Turner syndrome:

- Results of oestrogen treatment on development of secondary sexual characteristics, uterine dimensions and serum hormone levels. *Clin. Endocrinol. (Oxf)*. 2009;70(2):265–273.
166. **Labarta JI, Moreno ML, López-Siguero JP, Luzuriaga C, Rica I, Sánchez-del Pozo J, Gracia-Bouthelier R.** Individualised vs fixed dose of oral 17 β -oestradiol for induction of puberty in girls with Turner syndrome: An open-randomised parallel trial. *Eur. J. Endocrinol.* 2012;167(4):523–529.
167. **Ankarberg-Lindgren C, Kriström B, Norjavaara E.** Physiological estrogen replacement therapy for puberty induction in girls: A clinical observational study. *Horm. Res. Paediatr.* 2014;81(4):239–244.
168. **Zacharin M.** Pubertal induction in hypogonadism: Current approaches including use of gonadotrophins. *Best Pract. Res. Clin. Endocrinol. Metab.* 2015;29(3):367–383.
169. **Burt E, Davies MC, Yasmin E, Cameron-Pimblett A, Mavrellos D, Talaulikar V, Conway GS.** Reduced uterine volume after induction of puberty in women with hypogonadism. *Clin. Endocrinol. (Oxf)*. 2019;91(6):798–804.
170. **Bakalov VK, Shawker T, Cenicerros I, Bondy CA.** Uterine development in Turner syndrome. *J. Pediatr.* 2007;151(5):528–31, 531.e1.
171. **Holm K, Mosfeldt Laursen E, Brocks V, Müller J.** Pubertal maturation of the internal genitalia: an ultrasound evaluation of 166 healthy girls. *Ultrasound Obstet. Gynecol.* 1995;6(3):175–181.
172. **Salardi S, Orsini LF, Cacciari E, Bovicelli L, Tassoni P, Reggiani A.** Pelvic ultrasonography in premenarcheal girls: Relation to puberty and sex hormone concentrations. *Arch. Dis. Child.* 1985;60(2):120–125.

173. **Kelsey TW, Ginbey E, Chowdhury MM, Bath LE, Anderson RA, Wallace WHB.** A validated normative model for human uterine volume from birth to age 40 years. *PLoS One* 2016;11(6). doi:10.1371/journal.pone.0157375.
174. **Bae YJ, Zeidler R, Baber R, Vogel M, Wirkner K, Loeffler M, Ceglarek U, Kiess W, Körner A, Thiery J, Kratzsch J.** Reference intervals of nine steroid hormones over the life-span analyzed by LC-MS/MS: Effect of age, gender, puberty, and oral contraceptives. *J. Steroid Biochem. Mol. Biol.* 2019;193. doi:10.1016/j.jsbmb.2019.105409.
175. **Colvin CW, Abdullatif H.** Anatomy of female puberty: The clinical relevance of developmental changes in the reproductive system. *Clin. Anat.* 2013;26(1):115–129.
176. **Griffin I, Cole T, Duncan K, Hollman A, Donaldson M.** Pelvic ultrasound measurements in normal girls. *Acta Pædiatrica* 1995;84(5):536–543.
177. **Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, Cifkova R, De Muinck Keizer-Schrama S, Hogervorst E, Janse F, Liao L, Vlasisavljevic V, Zillikens C, Vermeulen N.** ESHRE Guideline: Management of women with premature ovarian insufficiency. *Hum. Reprod.* 2016;31(5):926–937.
178. **Langrish JP, Mills NL, Bath LE, Warner P, Webb DJ, Kelnar CJ, Critchley HOD, Newby DE, Wallace WHB.** Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. *Hypertension* 2009;53(5):805–811.
179. **Crofton PM, Evans N, Bath LE, Warner P, Whitehead TJ, Critchley HOD, Kelnar CJH, Wallace WHB.** Physiological versus standard sex steroid replacement in young women with premature ovarian failure: Effects on bone mass acquisition and

turnover. *Clin. Endocrinol. (Oxf)*. 2010;73(6):707–714.

180. **Hiort O, Cools M, Springer A, McElreavey K, Greenfield A, Wudy SA, Kulle A, Ahmed SF, Dessens A, Balsamo A, Maghnie M, Bonomi M, Dattani M, Persani L, Audi L.** Addressing gaps in care of people with conditions affecting sex development and maturation. *Nat. Rev. Endocrinol.* 2019;15(10):615–622.

Accepted Manuscript

Tables

Table 1 – Main etiologies of pubertal delay

CDGP: constitutional delay of growth and puberty; FHH functional hypogonadotropic hypogonadism, CHH: congenital hypogonadotropic hypogonadism; CAH: Congenital Adrenal Hypoplasia; MPHD: multiple pituitary hormone deficiencies; DSD: disorders of sex development.

Table 2 - Red flag features of CHH

CHH: congenital hypogonadotropic hypogonadism; UK: United Kingdom

Table 3 – Testosterone: types and routes of administration and characteristics

IM: intramuscular; TRT: testosterone replacement therapy; SEDDS: self-emulsifying drug delivery system

Table 4 - Estrogens: types, routes of administration and characteristics

E₂: estradiol; E₁: estrone, E₁S: estrone sulfate, EE: ethinylestradiol; CEE: conjugated equine estrogens; LC-MS: liquid chromatography–mass spectrometry.

Table 5 - Progestins: types, routes of administration and characteristics

MPA: medroxyprogesterone acetate; HRT: hormonal replacement therapy; MP: micronized progesterone; LC-MS: liquid chromatography–mass spectrometry.

Table 6 - Clinical approach in pubertal induction

hCG: human chorionic gonadotropin; FSH: Follicle-stimulating hormone; AMH: Anti-Müllerian Hormone; 17βE₂: 17β-estradiol; TV: testicular volume; US: ultrasound; RX: radiography; DXA: Dual-Energy X-ray Absorptiometry; BMD: bone mineral density.

Table 1. Main etiologies of pubertal delay

	Non-pathologic form	Pathologic forms		
Classification	CDGP	Central Hypogonadism		Primary Hypogonadism
		Organic	FHH	
Common causes	Unknown (genetic background?)	<ul style="list-style-type: none"> • CHH (normosmic CHH; Kallmann's syndrome) • CHARGE syndrome • CHH with CAH • MPHD • Hypothalamic-Pituitary region lesions (eg. craniopharyngiomas) • Metabolic diseases (eg. hemochromatosis) • hypophysitis • Infiltrative diseases • Thalassemia • Infection • Inflammatory (eg. Langerhans Cell Histiocytosis) • Granulomatous disease (eg. sarcoidosis) • Iatrogenic causes (eg. radiotherapy) • Other genetic syndromes (eg. Prader-Willi, Laurence Moon-Biedl, etc) 	<ul style="list-style-type: none"> • Chronic illness • Malnutrition • Excessive exercise • Stress • Medications • Other endocrine disorders (eg. hyperprolactinemia, hypothyroidism) 	<ul style="list-style-type: none"> • Klinefelter syndrome • Turner syndrome • Anorchia • Enzymatic defects • DSD (eg. gonadal dysgenesis) • LH/FSH resistance • Acquired forms (eg. chemo- and/or radio-therapies; autoimmune diseases, trauma, gonadal torsion)
Frequency (%)				
- Male	60-65	10	20	5-10
- Female	35	20	20	25

Adapted from: "Bollino et al. *Minerva Pediatr.* 2020;72(4):278–287" (5).

CDGP: constitutional delay of growth and puberty; FHH functional hypogonadotropic hypogonadism, CHH: congenital hypogonadotropic hypogonadism; CAH: Congenital Adrenal Hypoplasia; MPHD: multiple pituitary hormone deficiencies; DSD: disorders of sex development.

Table 2 – Red flag features of CHH

<u>Indicators of absent minipuberty</u>			<u>Non-reproductive phenotypes</u>		
	% among CHH patients*	% among UK population		% among CHH patients*	% among UK population
Microphallus	10%	<i>0.15% at birth</i>	Anosmia	45%	<i>2%, but not exclusively congenital</i>
Cryptorchidism	40%	<i>1.5% at 3 months</i>	Deafness	6%	<i>0.12% at birth (otoacoustic emission test)</i>
Bilateral cryptorchidism	20%	<i>0.4% by 3-12 months</i>	Cleft lip or palate	5%	<i>0.15% at birth</i>
Absent erections on morning diaper change	-	-	Digital abnormalities	5%	<i>0.1% at birth</i>
			Family history of CHH		

Composite data: Bonomi, EJE 2018; Quinton, Clin Endo 2001; Stamou, EJE 2017; Pitteloud, JCEM 2002; Quinton, personal data.

CHH: congenital hypogonadotropic hypogonadism; UK: United Kingdom.

Table 3 – Testosterone: types and routes of administration and characteristics

Drug	Formulations	Characteristics and Pharmacokinetics	Advantages	Disadvantages
<p>Intermediate-acting Testosterone esters for IM injection:</p> <p>Enanthate or mixture of different esters)</p>	<p>100, 200, 250, 400, 1.000, 2.000 mg vials</p>	<p>Viscous, oily liquid</p> <p>The esterification of its 17β-hydroxyl group makes its absorption much slower.</p> <p>Plasma half-life is about 4.5 days</p> <p>Steady state is achieved in 1-2 injections</p> <p>Standard doses for adult hypogonadal males (TRT): 100 mg IM every 7–10 days, or 250 mg every 2–3 weeks</p> <p>Initial dose for pubertal induction in younger adolescents with DP might be 50 mg monthly.</p>	<p>Wide experience and known efficacy in adolescents with delayed puberty.</p> <p>Low cost.</p> <p>Self-administration is possible.</p> <p>Widely available.</p>	<p>Wide fluctuations of testosterone levels may deeply affect mood, energy and libido.</p> <p>Frequent, painful injections (compliance at risk)</p> <p>Higher risk of erythrocytosis and other side effects</p>
<p>Long-acting Testosterone undecanoate for IM injection:</p>	<p>1000 mg/4 ml vials</p>	<p>Its viscous, oily solution and its long aliphatic hydrophobic side chain make its absorption slower and its half-life considerably longer (about 34 days).</p> <p>Testosterone serum levels reach their maximal levels about 10-12 days after each injection.</p> <p>Recommended injection interval in adult hypogonadal males (TRT) is 10 to 14 weeks. In order to achieve steady state more rapidly in such patients, a shorter interval (6 weeks) between 1st and 2nd doses is recommended.</p> <p>It can be used for pubertal induction only in older adolescents and adult males with delayed puberty, although with a few precautions (see text); it is not recommended in younger adolescents.</p>	<p>Much less frequent injections than with intermediate-acting testosterone esters (possibly better compliance).</p> <p>More stable testosterone concentrations than with intermediate-acting testosterone esters, therefore no swings in mood, energy, or libido.</p>	<p>Relatively painful injections</p> <p>Slow washout after withdrawal</p> <p>High cost</p> <p>Self administration is impractical</p> <p>Poor flexibility in dose modifications</p> <p>Limited clinical experience in adolescents with delayed puberty</p>
<p>Transdermal Testosterone gels</p>	<p>Single use sachets or tubes & multidose dispensers.</p>	<p>It must be applied every morning, on dry, intact skin.</p>	<p>Self-administration</p> <p>Flexible dose modification using the</p>	<p>Daily administration (compliance issues)</p>

	Testosterone concentration: 1%, 1.62% & 2%	<p>Once applied, it is rapidly absorbed through skin and is stored within the stratum corneum of epidermis, from which it is slowly and progressively released into the bloodstream.</p> <p>After the first administration, testosterone levels increase up to 4-5-fold within 24 hours, reaching the steady state after 2-3 days.</p> <p>Testosterone levels remain stable as long as gel is regularly administered: once withdrawn, testosterone serum levels fall within 96 hours.</p>	<p>multidose dispenser</p> <p>Stable testosterone concentrations, therefore no swings in mood, energy or libido</p> <p>Short half-life, therefore rapid washout after drug withdrawal (ex. after adverse events)</p>	<p>Allergic reactions</p> <p>Skin irritation</p> <p>Risk of skin-to-skin transmission</p> <p>Limited clinical experience in adolescents with delayed puberty</p> <p>High cost</p>
Oral Testosterone undecanoate	Tablets 40 mg	<p>It has a long, aliphatic, lipophilic chain which allows it to be absorbed through the intestinal lymphatic system, bypassing hepatic first pass effect and avoiding inactivation.</p> <p>It takes 2-6 hours after ingestion to reach its maximum serum levels</p> <p>It has a very short half-life and a 7% bioavailability</p>	<p>Easy and discreet self-administration</p> <p>Short half-life, therefore rapid washout after drug withdrawal (ex. after adverse events)</p> <p>No liver toxicity (as opposed to methyltestosterone and 17-α derivatives)</p>	<p>Its absorption is unreliable and dependent on dietary fat intake: without a fat-rich meal it is minimally absorbed</p> <p>Short duration of action</p> <p>Due to its short half-life, multiple daily administrations may be required, which could lead to compliance issues</p> <p>Even with multiple daily administrations, there are daily swings in testosterone levels.</p> <p>Not widely available</p>
Subdermal Testosterone pellets	Subdermal implants 100 mg, 200 mg	<p>They are implanted subcutaneously within the lower abdominal wall</p> <p>Testosterone is progressively and constantly absorbed into the systemic circle through a uniform erosion of the pellet's surface, through which it is released</p> <p>Since in this way testosterone does not undergoes hepatic first pass effect, its absorption and biodisponibility are virtually</p>	<p>Flexible dosage is feasible by combining different pellets of 100 or 200 mg</p> <p>Stable testosterone concentrations with no swings in their levels except for a rapid increase in the first days after impantation, due to an accelerated release of testosterone</p> <p>No need for injections or frequent</p>	<p>Minor surgery is required for pellet implantation and regular substitution</p> <p>Risk of implant extrusion, bleeding or infection</p> <p>High cost</p>

		<p>complete</p> <p>A single 200 mg pellet releases about 1.3 mg/die of testosterone.</p> <p>In adult hypogonadal men the implantation of 3-6 200 mg pellets provides physiological daily dosage of testosterone for 4-6 months.</p>	<p>administration, therefore better compliance (useful for noncompliant patients)</p>	
<p>Oral Testosterone undecanoate (SEDDS formulation)</p>	<p>Oral capsules</p>	<p>It's a self-emulsifying drug delivery system: it combines a mixture of hydrophilic and lipophilic excipients that enable the solubilization of TU in the gut, so that after oral administration it can be absorbed through the intestinal lymphatic system irrespective of the lipid content of the previous meal.</p> <p>It bypasses first hepatic effect and therefore inactivation</p> <p>Once absorbed into the systemic circulation, its undecanoic acid molecules are cleaved by non-specific esterases and subsequently metabolized; TU is therefore turned into testosterone.</p> <p>After administration, peak testosterone levels are achieved after about 2-4 hours and then progressively decrease down to the lower-end of normal range after about 12 hours from administration.</p>	<p>Easy and discreet self-administration</p> <p>The lipid-content of meals does not interfere with TU absorption</p> <p>No liver toxicity</p>	<p>Being a SEDDS formulation, capsules cannot be cut</p> <p>High degree of enzymatic cleavage of testosterone from TU can occur during blood-sample handling, possibly leading to artefactually higher levels of testosterone when dosed.</p> <p>Mild gastrointestinal adverse effects</p> <p>Increase in mean systolic blood pressure of 3-5 mmHg</p> <p>No studies have evaluated its efficacy for pubertal induction</p>
<p>Subcutaneous enanthate testosterone</p>	<p>Auto-injector</p>	<p>Testosterone enanthate is administered in an oil solution, via an auto-injector devised to inject highly viscous solutions through a 5/8-inch, 27-gauge needle subcutaneously</p> <p>Weekly injections of 50 mg of subcutaneous testosterone lead to a rapid, yet temporary, increase of testosterone levels, which</p>	<p>Reduced sensation of pain and fine-needle entry</p> <p>Auto-injector is easy to use, therefore self-administration is easily feasible</p> <p>No risk for skin-to-skin transmission</p> <p>Reduced variability of testosterone</p>	<p>Higher frequency of injections compared to other injectable formulations</p> <p>No studies have evaluated its efficacy for pubertal induction</p>

		<p>progressively fall to baseline right before the following administration;</p> <p>Conversely, weekly injections of 100 mg subcutaneous testosterone lead to progressively higher levels of testosterone during the first three weeks, when a steady-state is reached: after 4 weeks, testosterone exposure is greater than the one provided during the first week of treatment.</p>	<p>levels through time, therefore less risk for fluctuations of mood, energy or libido</p>	
--	--	---	--	--

TRT: testosterone replacement therapy; IM: intramuscular; SEDDS: self-emulsifying drug delivery system.

Table 4 – Estrogens: types, routes of administration and characteristics

Drug	Formulations	Characteristics and Pharmacokinetics	Advantages	Disadvantages
17β-estradiol (E₂)	<p>Oral tablets: 1 & 2 mg (0.5 mg available in some countries)</p> <p>Equivalent dose: 2–4 mg daily for a young hypogonadal adult woman</p>	<p>Bioidentical E₂, or esterified as hemihydrate or valerate.</p> <p>It undergoes hepatic first pass effect, after which its systemic bioavailability is about 5%.</p> <p>Its levels rise rapidly, maintain a plateau for up to 12 hours and decrease slowly afterwards, reaching steady state within several days of administration.</p> <p>E₂ is metabolized to E₁ and E₁S that serve as a hormonally inert reservoir from which E₂ is continuously delivered after reversion</p>	<p>Greater safety compared to EE (lower risk of thrombosis and hypertension) and CEE (lower risk of thrombosis)</p> <p>Greater efficacy compared to EE or CEE</p> <p>Levels are measurable for treatment monitoring by either immunoassay or LC-MS.</p> <p>Well accepted by patients</p>	<p>The low doses required for the early phase of pubertal induction can only be achieved with careful use of a tablet cutter device and/or by resorting to alternate day dosing.</p> <p>It undergoes first pass effect.</p>
	<p>Transdermal matrix patches: 25, 37.5, 50, 75 or 100 µg, typically changed twice weekly</p> <p>Equivalent dose: 100–200 mg for a young hypogonadal adult woman</p>	<p>Bioidentical E₂</p> <p>It is absorbed into skin capillaries and continuously delivered into the bloodstream (depot effect in skin and subcutaneous fat)</p> <p>Estradiol plasma levels remain constant for the duration of patch life.</p> <p>No accumulation of estrogens metabolites or conjugates in blood.</p>	<p>Patches can be cut to administer precise fractional doses.</p> <p>Greater safety than EE (lower risk of hypertension) and oral E₂ (lower risk of thrombosis).</p> <p>Levels are measurable for treatment monitoring by either immunoassay or LC-MS.</p> <p>Better absorption and more physiological estrogen milieu.</p> <p>It bypasses first pass effect, therefore it</p>	<p>It may not be accepted by patients (visible patch, worn constantly).</p> <p>Poor adhesion of patches</p> <p>Skin reactions</p>

	<p>E2 hemihydrate sachets, or E2 0.06% multidose dispenser</p> <p>Equivalent dose: 1–2 g daily for a young hypogonadal adult woman</p>		<p>has neutral effect on lipids, coagulation profile or other markers of hepatic metabolism.</p> <p>Possible overall benefit over oral estrogens for long-term ERT</p>	<p>No published data for pubertal induction, but extensive clinical experience for inducing feminisation of older transgender teenagers.</p>
Ethinylestradiol (EE)	<p>Oral tablets: 10, 20, or 30 µg</p> <p>Equivalent dose: 20–30 µg for a young hypogonadal adult woman</p>	<p>Synthetic E₂ analogue.</p> <p>It binds estrogen receptors with high affinity (particularly in the central nervous system)</p> <p>17α-ethinyl substitution prevents its inactivation in the liver, but it activates renin.</p> <p>It is more stable and active in the bloodstream compared to E₂</p> <p>It undergoes a more pronounced hepatic effect</p> <p>After administration, serum concentrations have both a rapide rise (1–3 h) and decline</p> <p>Oral bioavailability is 38–48%</p>	<p>Wide clinical experience</p> <p>Well accepted by patients</p>	<p>Unphysiological type of estrogen</p> <p>Its first pass effect leads to a more pronounced impact on estrogen-dependent hepatic serum parameters as compared to E₂</p> <p>The low doses required for the early phase of pubertal induction can only be achieved with careful use of a tablet cutter device and/or by resorting to alternate day dosing.</p> <p>It is no longer easily available</p> <p>Possible suboptimal outcomes (uterine maturation)</p> <p>It is not measurable for treatment monitoring</p> <p>It is less safe than other options (risk of renin-induced hypertension and venous thrombosis)</p>
Conjugated equine estrogens (CEE)	<p>Oral tablets: 0.625 & 1.25 mg (0.3 & 0.9 mg available in some countries).</p> <p>Equivalent dose: 1.25–2.5 mg for a young hypogonadal adult woman</p>	<p>Extracted and purified from pregnant mares' urine and containing a large number of different estrogenic compounds of different potency. Variable effects depending on the target tissue.</p> <p>More pronounced effect than E₂ on the production of hepatic proteins, with</p>	<p>Wide clinical experience.</p> <p>Well accepted by patients</p> <p>Levels are measurable for treatment monitoring by immunoassay, but not LC-MS.</p>	<p>Unphysiological type of estrogen</p> <p>It is associated with wide variations in the biologic effects</p> <p>The low doses required for the early phase of pubertal induction can only be achieved with careful use of a tablet cutter device and/or by resorting to alternate day dosing.</p>

		higher ratio between hepatic and clinical effect.		<p>First pass effect is more pronounced than for oral E₂ (higher ratio between hepatic and clinical effects)</p> <p>Risk of venous thrombosis</p>
--	--	---	--	--

E₂: estradiol; E₁: estrone; E₁S: estrone sulfate; EE: ethinylestradiol; CEE: conjugated equine estrogens; LC-MS: liquid chromatography–mass spectrometry.

Table 5 – Progestins: types, routes of administration and characteristics

Drug	Formulations	Characteristics and Pharmacokinetics	Advantages	Disadvantages
Medroxyprogesterone acetate (MPA)	Oral tablets: 2.5, 5 or 10 mg Equivalent dose for a young hypogonadal adult woman: 7.5–12.5 mg daily (days 1–12/14 of calendar month) or 2.5–5 mg daily (continuous)	Synthetic progestogen It has reduced inactivation rate and increased hormonal potency compared to native form. After oral administration, its bioavailability is high. It binds with high affinity the progesterone receptor, antagonizing the estrogen-induced endometrial proliferation Considerable glucocorticoid effects, which causes an upregulation of the thrombin receptor and stimulates the procoagulant activity It also has weak androgenic properties.	Wide experience. Great endometrial safety	Its moderate androgen effects can affect patients both clinically and on lipidic and glucose metabolism. Upregulation of thrombin receptor (pro-thrombotic effect). It may lead to weight gain and fluid retention.
Micronized progesterone (MP)	Oral capsules; 100 or 200 mg. Equivalent dose for a young hypogonadal adult woman: 200–300 mg daily (days 1–12/14 of calendar month) or 100–200 mg daily (continuous)	Bioidentical progesterone. It has progestogenic and antiestrogenic activities on the endometrium and cervix, an anti-mineralocorticoid effect and a ‘non-receptor’ mediated antiandrogenic effect. It undergoes extensive metabolism in the gastrointestinal tract and liver, which leads to both low bioavailability and many circulating metabolites, some of which exert hormonal activities (e.g., pregnanolone sedative effects via GABA-A receptor). Its micronized formulation, suspended in oil and packaged in a gelatine capsule, increases bioavailability.	High selectivity and lack of glucocorticoid activity Substantial safety on breast, possibly with a more favorable effect on breast tissue than synthetic progestogens such as MPA Neutral in respect of cardiovascular risk and venous thromboembolism. Neutral on body composition, blood pressure, glucose and lipid metabolism and markers of endothelial function.	Drowsiness and dizziness Worse cycle control than synthetic progestogens. More frequent breakthrough bleeding than synthetic progestogens when used continuously. Some concerns about less effective protection for uterine hyperplasia and cancer compared to synthetic progestogens such as MPA

		Recommended doses (sequentially for 12–14 days/month at 200 mg/day) proved to be effective in endometrial protection, despite low circulating levels of progesterone (as measured by reliable methods like LC–MS).		
Norethisterone acetate (NEA)	Oral tablets: 0.5, 1 mg, 5 mg (lower doses only available as part of combined HRT): Equivalent doses for a young hypogonadal adult woman 1–2.5 mg daily (days 1–12 of calendar month or pack cycle) or 0.5–1 mg daily (continuously).	Synthetic progestogen Highest potency on endometrium and cervix. Highest androgenic activity. Oral bioavailability approximately 64%. Extensively metabolized primarily in the liver.	Neutral on venous thromboembolism and blood pressure. Minimal glucocorticoid activity.	Being the most androgenic progestogen, it affects patients both clinically and on lipids & glucose metabolism. Highest risk of hepatotoxicity.
	Transdermal patches: 170 µg, changed twice weekly. Only available as part of combined HRT.	Steady-state concentrations achieved within 24 hours.		
Dydrogesterone	Oral tablets: 2.5, 5 or 10 mg. Currently only available just as part of combined HRT. Equivalent dose for a young hypogonadal adult woman: 10 mg daily (days 1–14	Synthetic progestogen. Highly selective progestogenic and antiestrogenic activities on the endometrium and cervix Weak anti-mineralcorticoid properties No androgenic effects. Rapidly absorbed, it has a bioavailability of 28%.	High selectivity and lack of glucocorticoid/androgenic activity. Neutral in respect of cardiovascular risk and venous thromboembolism. Neutral on body composition, blood pressure, glucose and lipid metabolism and markers of endothelial function.	Headaches. Not available as a separate tablet.

	of calendar month or pack cycle) or 5 mg daily taken continuously.	Completely metabolized to 20-dihydroprogesterone (DHD), resulting in increased half-life (14–17 hours).		
--	--	---	--	--

MPA: medroxyprogesterone acetate; HRT: hormonal replacement therapy; MP: micronized progesterone; LC-MS: liquid chromatography–mass spectrometry.

Table 6 – Clinical approach in pubertal induction

Regimen proposed	Follow up			
	Clinical examination		Lab and instrumental tests	
MALE				
<p>Testosterone</p> <p>Testosterone esters: initial dose of testosterone enanthate 50 mg i.m./4 weeks, to escalate every ≈6 months up to adult dose (≈250 mg i.m./2-4 weeks) in 24-36 months (even 18 months in older patients)</p> <p>Testosterone gel: initial dose 10 mg (e.g. testosterone gel 2% 1 puff) every second day to escalate every ≈6 months up to adult dose (≈40-60 mg daily) in 24-36 months (even 18 months in older patients)</p> <p>Gonadotropins (for HH patients)</p> <p>hCG: Initial dose 250 UI sc twice weekly to escalate every ≈6 months up to adult dose (≈1500 UI three times weekly) in 24-36 months (even 18 months in older patients) + FSH: 75-150 UI sc three times weekly (consider pre-treatment before hCG for 3-6 months)</p>	<ul style="list-style-type: none"> · genital development, TV* (Prader orchidometer) and virilization · height, weight and growth rate · blood pressure · compliance and satisfaction · side effects appearance 	<p>every 4-6 months (or at any change of dose)</p> <p>*less useful in stated hypergonadotropic hypogonadism (e.g. Klinefelter)</p>	<ul style="list-style-type: none"> · serum testosterone and hematocrit · AMH and Inhibin B · testicular US · wrist RX for bone age · DXA for BMD · semen analysis 	<p>every 4-6 months (or at any change of dose)</p> <p>baseline and after gonadotropins stimulation in HH</p> <p>When indicated by physical examination</p> <p>annually up to final height achievement</p> <p>at baseline (selected cases) and at least 2 years after treatment initiation</p> <p>at conclusion in HH patients treated with gonadotropins</p>
FEMALE				
<p>Transdermal 17βE₂: initial dose ½–¼ 25 µg patch (based on weight) only at night-time for the first 6 months then to escalate every ≈6 months up to adult dose (50-100 µg patch) in 24-36 months (even 18 months in older patients)</p> <p>Oral 17βE₂: initial dose 0.5 mg every second day to escalate every ≈6 months up to adult dose (2 mg daily) in 24-36 months (even 18 months in older patients)</p> <p>+ Progestin: Start 200–300 mg micronized oral progesterone for 12-14 consecutive</p>	<ul style="list-style-type: none"> · breast development and feminization · height, weight and growth rate · blood pressure · compliance and satisfaction 	<p>every 4-6 months (or at any change of dose)</p>	<ul style="list-style-type: none"> · serum estradiol · uterine US · wrist RX for bone age 	<p>every 4-6 months (or at any change of dose)</p> <p>after the completion of induction or periodically to evaluate the endometrial thickness</p> <p>annually up to final height achievement</p>

day/month at reaching of adult dose either after about 2 years of unopposed estrogen or earlier if breakthrough bleeding occurs	· side effects appearance		· DXA for BMD	at baseline (selected cases) and at least 2 years after treatment initiation
---	---------------------------	--	---------------	--

HH: hypogonadotropic hypogonadism; hCG: human chorionic gonadotropin; FSH: Follicle-stimulating hormone; AMH: Anti-Müllerian Hormone; $17\beta E_2$: 17β -estradiol; TV: testicular volume; US: ultrasound; RX: radiography; DXA: Dual-Energy X-ray Absorptiometry; BMD: bone mineral density.

ESSENTIAL POINTS

- 1) The optimal age to begin treatment in patients with known hypogonadism has not been universally established yet, but a prompt initiation of treatment after diagnosis of DP is recommended within the physiological time frame whenever possible.
- 2) Pubertal induction must be tailored according to each patient's clinical history and needs. Treatment should not only lead to genital maturation and development of secondary sexual characteristics, but also promote psychosexual development.
- 3) The most consolidated therapeutic strategy for pubertal induction in males involves intramuscular testosterone esters (*i.e.*, testosterone enanthate); however, in the last years newer testosterone formulations, such as intramuscular testosterone undecanoate and testosterone gel, have been used with promising results.
- 4) Gonadotropin treatment for pubertal induction in males with hypogonadotropic hypogonadism represents a good alternative to exogenous androgens, with the advantages of potentially increasing testicular volume, inducing spermatogenesis, and promoting spontaneous descent of testes in patients with cryptorchidism.
- 5) Pubertal induction in females involves the administration of both estrogens (to promote feminization) and progesterone (to prevent endometrial hyperplasia): the most recent acquisitions in the field seem to suggest that transdermal 17β -estradiol and micronized progesterone represent the most physiological formulations for this purpose.

Accepted Manuscript